<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cell Mol Life Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Cell. Mol. Life Sci</journal-id>
<journal-title-group>
<journal-title>Cellular and Molecular Life Sciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">1420-682X</issn>
<issn pub-type="epub">1420-9071</issn>
<publisher>
<publisher-name>Springer International Publishing</publisher-name>
<publisher-loc>Cham</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26979166</article-id>
<article-id pub-id-type="pmc">4894934</article-id>
<article-id pub-id-type="publisher-id">2175</article-id>
<article-id pub-id-type="doi">10.1007/s00018-016-2175-4</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kalkman</surname>
<given-names>Hans O.</given-names>
</name>
<address>
<phone>+41 61 362 0110</phone>
<email>hans.kalkman@bluewin.ch</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
<xref ref-type="aff" rid="Aff2"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feuerbach</surname>
<given-names>Dominik</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><label></label>Neuroscience Research, NIBR, Fabrikstrasse 22-3.001.02, 4002 Basel, Switzerland </aff>
<aff id="Aff2"><label></label>Gänsbühlgartenweg 7, 4132 Muttenz, Switzerland </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>15</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>15</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2016</year>
</pub-date>
<volume>73</volume>
<fpage>2511</fpage>
<lpage>2530</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>11</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>25</day>
<month>2</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>3</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2016</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>The clinical development of selective alpha-7 nicotinic acetylcholine receptor (α7 nAChR) agonists has hitherto been focused on disorders characterized by cognitive deficits (e.g., Alzheimer’s disease, schizophrenia). However, α7 nAChRs are also widely expressed by cells of the immune system and by cells with a secondary role in pathogen defense. Activation of α7 nAChRs leads to an anti-inflammatory effect. Since sterile inflammation is a frequently observed phenomenon in both psychiatric disorders (e.g., schizophrenia, melancholic and bipolar depression) and neurological disorders (e.g., Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis), α7 nAChR agonists might show beneficial effects in these central nervous system disorders. In the current review, we summarize information on receptor expression, the intracellular signaling pathways they modulate and reasons for receptor dysfunction. Information from tobacco smoking, vagus nerve stimulation, and cholinesterase inhibition is used to evaluate the therapeutic potential of selective α7 nAChR agonists in these inflammation-related disorders.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Dyskinesia</kwd>
<kwd>Autism</kwd>
<kwd>Suicide</kwd>
<kwd>Lithium</kwd>
<kwd>GSK3</kwd>
<kwd>CREB</kwd>
<kwd>Nrf2</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer International Publishing 2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p>Alpha-7 nicotinic acetylcholine receptors (α7 nAChRs) are expressed in the central nervous system (CNS) and are thought to play a role in a wide variety of psychiatric and neurological disorders. Peripheral and CNS immune cells strongly express α7 nAChRs; activation of α7 nAChRs on these cells has been shown to suppress inflammatory processes. Since inflammation is involved in several psychiatric disorders, as well as in basically all neurological disorders, specific α7 nAChR agonists could display therapeutic effects. In the current review, we summarize information on receptor expression, the intracellular signaling pathways modulated by these receptors, reasons for receptor dysfunction, clinical evidence for altered α7 nAChRs, and we conclude with a discussion about potential indications for selective α7 nAChRs agonists.</p>
</sec>
<sec id="Sec2">
<title>Expression of α7 nAChR</title>
<p>Distinct from most nicotinic acetylcholine receptors (nAChR), the α7-subtype mainly forms homomeric, rather than heteromeric pentamers. In the central nervous system, including the human brain, such nicotinic-α7 homomeric pentamers are expressed by pyramidal and interneurons [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>]. Apart from neurons, immature (doublecortin positive) granule cells [<xref ref-type="bibr" rid="CR4">4</xref>], astrocytes [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR7">7</xref>], and microglia cells [<xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR13">13</xref>] also express the α7 nAChR. Finally, NG2-positive cells (these are oligodendrocyte precursors) also express α7 nAChRs [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. The dogma that α7 nAChRs exclusively assemble as homomeric pentamers was recently overturned by the discovery that α7 subunits also form heteromeric pentameric ion channels with β2 subunits [<xref ref-type="bibr" rid="CR15">15</xref>]. Such heteromeric α7β2 channels were found on cholinergic projection neurons in mouse and human basal forebrain [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Concerning function, activation of α7 nAChRs results in strong calcium and sodium influxes, which in the case of a presynaptic location facilitates neurotransmitter release [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. A postsynaptic localization on parvalbumin-positive GABA neurons suggests a role in synchronized oscillatory output of pyramidal neurons.</p>
<p>Outside the brain, the receptor is expressed on several cell types of the immune system. This includes monocytes [<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref>], dendritic cells [<xref ref-type="bibr" rid="CR22">22</xref>], macrophages [<xref ref-type="bibr" rid="CR23">23</xref>–<xref ref-type="bibr" rid="CR26">26</xref>], T-cells [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], and B-cells [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The receptor has also been identified on additional cell types known to play a role in the host’s defense against pathogenic organisms. Examples are the microvascular endothelium [<xref ref-type="bibr" rid="CR31">31</xref>], keratinocytes [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], placenta [<xref ref-type="bibr" rid="CR34">34</xref>], bronchial epithelial cells [<xref ref-type="bibr" rid="CR35">35</xref>], platelets [<xref ref-type="bibr" rid="CR36">36</xref>], adipocytes [<xref ref-type="bibr" rid="CR37">37</xref>], and synoviocytes [<xref ref-type="bibr" rid="CR38">38</xref>]. During wound healing, expression of α7 nAChRs is transiently observed on fibrocytes and myofibroblasts in the wound zones [<xref ref-type="bibr" rid="CR39">39</xref>]. Completing this list, α7 nAChRs were detected in mouse testes, in mouse and human sperm (where they modify sperm motility [<xref ref-type="bibr" rid="CR40">40</xref>]), in rat superior cervical ganglia [<xref ref-type="bibr" rid="CR41">41</xref>], and in group-IV muscle afferent neurons [<xref ref-type="bibr" rid="CR42">42</xref>].</p>
<p>Not unexpectedly, numerous cell lines <italic>endogenously</italic> express α7 nAChR too. This includes rat PC12-cells [<xref ref-type="bibr" rid="CR43">43</xref>], human SH-SY5Y neuroblastoma cells [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], mouse RAW264.7 [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>], the human leukemic T-cell line MOLT3 [<xref ref-type="bibr" rid="CR48">48</xref>], the human monocyte U937 cell line [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR49">49</xref>], and immortalized human T-lymphocyte ‘Jurkat’ cells [<xref ref-type="bibr" rid="CR27">27</xref>]. <italic>Recombinant</italic> expression has also been achieved in cell lines that endogenously express the chaperones required for α7 nAChR expression, e.g., SH-EP1 cells [<xref ref-type="bibr" rid="CR50">50</xref>], SH-SY5Y [<xref ref-type="bibr" rid="CR51">51</xref>], or GH3 cells [<xref ref-type="bibr" rid="CR52">52</xref>].</p>
<p>With respect to the above-listed localizations of α7 nAChR, a word of caution is needed, since some expression studies are confounded by the use of tools that also detect a distinct, duplicated α7-like protein ‘dupα7’ [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR53">53</xref>], by the use of antibodies which recognize cross-reacting epitopes [<xref ref-type="bibr" rid="CR54">54</xref>] or by the use of the non-selective radioligand MLA (besides α7 nAChRs this compound also binds to nicotinic α3/α6β2β3* receptors, see [<xref ref-type="bibr" rid="CR55">55</xref>]).</p>
<p>In addition to expression on the cell surface, an intracellular localization of α7 nAChRs has been observed in brain mitochondria [<xref ref-type="bibr" rid="CR56">56</xref>]. In this organelle, the α7 nAChR may assemble with β2 subunits where it presumably influences pore formation and cytochrome-c release [<xref ref-type="bibr" rid="CR57">57</xref>].</p>
</sec>
<sec id="Sec3">
<title>Intracellular signaling pathways</title>
<p>In mouse hippocampal neurons, α7 nAChRs are characterized by rapid activation and desensitization. The fractional calcium current (<italic>P</italic><sub>f</sub>) has been assessed and found to be 6.1 [<xref ref-type="bibr" rid="CR58">58</xref>]. This indicates that in neurons α7 nAChRs have a special role in the modulation of intracellular calcium, enabling substantial calcium entry at resting or hyperpolarized membrane potential, which is different compared to other nAChRs, but similar to NMDA receptors at depolarized membrane potential. However, thus far, it is not known if this also holds true for α7 nAChRs in other cells (e.g., immune cells). The intracellular pathways following α7 nAChR activation in non-neuronal cells involve calcium influx through the channel pore, which then triggers calcium-induced calcium release from ryanodine- and IP3-dependent stores [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Further long-lasting intracellular pathways involve activation of intracellular phosphatases and kinases, which trigger signaling events <italic>independent</italic> of an ion flux (which implies that the α7 nAChR acts as metabotropic receptor) [<xref ref-type="bibr" rid="CR60">60</xref>]. For instance, activation of α7 nAChRs leads to stimulation of adenylate cyclase-1 and thus to increases in cAMP levels [<xref ref-type="bibr" rid="CR61">61</xref>]. This in turn stimulates protein kinase A (PKA), which may result in further signaling events such as CREB activation [<xref ref-type="bibr" rid="CR61">61</xref>] and GSK3 inhibition [<xref ref-type="bibr" rid="CR62">62</xref>]. Activation of the α7 nAChR on non-neuronal cells inhibited TLR3-, TLR4- or TLR9-induced transcription and release of inflammatory cytokines [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. One of the intracellular signaling cascades described in this context is a pathway that involves JAK2-mediated tyrosine-phosphorylation of the p85 subunit of PI3 K, activation of Akt and CREB, and subsequent inhibition of (or competition with) NFκB [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR63">63</xref>] (see Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Egea and colleagues emphasize that this pathway furthermore leads to activation of the transcription factor Nrf2, which is important for transcription of numerous anti-oxidative proteins and for the induction of an anti-inflammatory phenotype of microglia cells [<xref ref-type="bibr" rid="CR64">64</xref>]. Alternatively, downstream signaling towards NFκB may involve JAK2 activation of STAT3 [<xref ref-type="bibr" rid="CR65">65</xref>–<xref ref-type="bibr" rid="CR68">68</xref>] (see Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Finally, activation of α7 nAChRs can result in inhibition of p38 MAP-kinase [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. A functional consequence of this latter pathway is inhibition of the <italic>release</italic> of inflammatory mediators like TNFα and HMGB1 [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Schematic anti-inflammatory signaling pathways activated by nAChR α7. Stimulation of nAChR α7 activates Jak2 leading to inhibition of NFκB and GSK3 but also to CREB activation. A separate signaling cascade involves activation of PKA and AKT enabling the nuclear translocation of Nrf2 (NFE2L2), which drives expression of HMOX1 (HO-1). This pathway elicits potent anti-inflammatory and neuroprotective effects</p></caption><graphic id="MO1" xlink:href="18_2016_2175_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec4">
<title>The anti-inflammatory activity of α7 nAChR stimulation</title>
<p>As early as 1998, Sugano et al. [<xref ref-type="bibr" rid="CR49">49</xref>] described that nicotine displayed an anti-inflammatory activity involving inhibition of NFκB-signaling. Following this observation, it was shown that the receptor responsible for this response was the α7 nAChR subtype [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Moreover, it was shown that the anti-inflammatory effect of electrical stimulation of the vagus nerve was also mediated by the α7 nAChR [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Notably, after splenectomy the beneficial effects of vagus nerve stimulation were lost [<xref ref-type="bibr" rid="CR71">71</xref>], but some controversy still exists about the exact localization of the α7 nAChRs involved in the response to vagus nerve stimulation. The vagus nerve is supposed to activate the celiac ganglion, which is the origin of the adrenergic splenic nerve. According to one scenario, the splenic nerve releases noradrenaline onto <italic>memory</italic> T-cells (CD4<sup>+</sup> CD44<sup>high</sup>, CD62L<sup>low</sup>), resulting in synthesis and release of acetylcholine that activates α7 nAChRs on spleen-macrophages [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. The alternative proposal assumes that the α7 nAChRs are localized postsynaptically in the celiac ganglion. This view is supported by data showing that postganglionic stimulation of the splenic nerve still results in an anti-inflammatory response, even in mice with a genetic deletion of the α7 nAChR [<xref ref-type="bibr" rid="CR74">74</xref>]. However, in a critical review Martelli [<xref ref-type="bibr" rid="CR75">75</xref>] proposes that efferent vagus nerve stimulation achieves its anti-inflammatory effect via a non-neuronal (humoral) pathway. It is evident that this is an area that is still very much in development. Interestingly, activation of glucocorticoid receptors increases the expression of α7 nAChRs [<xref ref-type="bibr" rid="CR76">76</xref>]. This implies that the anti-inflammatory activity of glucocorticoids may include a nicotinergic mechanism. Overall, given the expression pattern, the cellular signaling cascades, and information from vagus nerve stimulation, the data strongly indicate that activation of the α7 nAChR suppresses the responsiveness of the immune system.</p>
<p>Surprisingly, whereas the activity of positive allosteric modulators (PAMs) in animal models of learning/memory or on evoked potentials is well documented (see [<xref ref-type="bibr" rid="CR77">77</xref>] for a recent review), there is a paucity of reports on their anti-inflammatory activity. In this context, PNU-120596 has been shown to attenuate TNFα and IL-6 in a rodent model of inflammatory pain. These findings have been recently corroborated with a different molecule (“PAM-2,” [<xref ref-type="bibr" rid="CR78">78</xref>]). Along the same lines several reports have shown that α7 nAChR PAMs reduce brain injury and improve neurological function after focal cerebral ischemia in rats [<xref ref-type="bibr" rid="CR79">79</xref>–<xref ref-type="bibr" rid="CR81">81</xref>].</p>
<p>Notably, the anti-inflammatory response to α7 nAChR stimulation also occurs in the brain. Thus, activation of α7 nAChRs is known to alter the phenotype of both macrophages and microglia from an M1-like to an M2-like phenotype [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. Consequently, any dysfunction in the α7 nAChR and its signaling processes could tip the balance towards more inflammation.</p>
</sec>
<sec id="Sec5">
<title>Reasons for dysfunction of the α7 nAChR</title>
<p>Dysfunction of α7 nAChRs may have a variety of causes. For adequate membrane insertion, the α7 nAChR has to be assembled first as a pentamer and is thereafter shuttled to the plasma membrane. This process requires several chaperone molecules such as RIC3, SLURP1, Lynx1, EPHB2, or PICK1, and evidently, their dysfunction could affect receptor level and function [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR84">84</xref>–<xref ref-type="bibr" rid="CR88">88</xref>]. In addition, transcription of the α7 nAChR can be diminished by heterozygotic or homozygotic 15q13.3 microdeletions [<xref ref-type="bibr" rid="CR89">89</xref>], by methylation of the promotor [<xref ref-type="bibr" rid="CR90">90</xref>] or by MeCP2 (methyl CpG binding protein 2) dysfunction [<xref ref-type="bibr" rid="CR91">91</xref>].</p>
<p>Moreover, activity of the α7 nAChR is modified by phosphorylation. An as yet undefined tyrosine-phosphorylated protein was shown to inhibit the functional activity of the α7 nAChR, whereas tyrosine kinase inhibition by genistein enhanced surface expression of the α7 nAChR [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR92">92</xref>] or its function [<xref ref-type="bibr" rid="CR51">51</xref>]. Serine-phosphorylation of the α7 nAChR can influence function too. It has been reported that activation of D1/D5 dopamine receptors attenuated α7 nAChR currents via PKA-mediated phosphorylation of the serine residue 365 in the M3–M4 cytoplasmic loop of the channel [<xref ref-type="bibr" rid="CR93">93</xref>]. Other possibilities have been proposed as well. For instance, diminished signaling of α7 nAChR might result from increased levels of the purported endogenous α7 nAChR inhibitor, kynurenic acid [<xref ref-type="bibr" rid="CR94">94</xref>], though conflicting data have been reported too [<xref ref-type="bibr" rid="CR95">95</xref>]. Also cholinergic input may be dysfunctional [<xref ref-type="bibr" rid="CR69">69</xref>], or the signaling pathway downstream of the receptor may be altered [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. Furthermore, dysfunction of the α7 nAChR could result from the presence of the CHRFAM7-gene. This gene encodes a dominant negative variant of the α7 nAChR [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR96">96</xref>] and is unique for humans [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. Transcripts, often described as ‘dupα7’, have been found in the promyelocytic leukemia cell line HL-60 [<xref ref-type="bibr" rid="CR26">26</xref>], monocyte cell lines (THP1, U937, and Mono-Mac6 [<xref ref-type="bibr" rid="CR98">98</xref>]), and neuroblastoma cell lines (SH-SY5Y, IMR32 [<xref ref-type="bibr" rid="CR98">98</xref>]). High levels of dupα7 transcripts have also been described in native immune cells such as peripheral blood monocytic cells, lymphocytes and synoviocytes, and in lower amounts also in human brain tissue [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR53">53</xref>].</p>
</sec>
<sec id="Sec6">
<title>Rapid metabolism of acetylcholine and receptor desensitization</title>
<p>Cholinergic innervation in the brain arises mainly from two sources. Cholinergic neurons from the medial septal nucleus innervate the hippocampus [<xref ref-type="bibr" rid="CR99">99</xref>], whereas cholinergic nerves from the basal forebrain (including the nucleus basalis Meynert) project to the cortex, amygdala, caudate nucleus, putamen, and thalamus [<xref ref-type="bibr" rid="CR100">100</xref>]. Acetylcholine locally released by cholinergic neurons is assumed to cross the synaptic cleft despite effective catabolism by cholinesterases [<xref ref-type="bibr" rid="CR101">101</xref>]. However, it is less clear whether volume transmission to extrasynaptic neuronal sites is sufficiently high to lead to relevant α7 nAChR stimulation. Outside the brain, high levels of cholinesterases are found in the blood and therefore it has been questioned whether α7 nAChRs on, for example, circulating immune cells will be exposed to levels of acetylcholine that are sufficient for activation [<xref ref-type="bibr" rid="CR102">102</xref>]. Further doubts about the physiological relevance of α7 nAChRs relate to their rapid desensitization [<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. However in the latter case, there are two counter-arguments. In the first place, α7 nAChRs not only rapidly desensitize, they also quickly recover [<xref ref-type="bibr" rid="CR105">105</xref>]. The second argument is that intracellular effects are presumably more sustained and therefore could outlast receptor desensitization. Vijayaraghavan et al. [<xref ref-type="bibr" rid="CR6">6</xref>] provide yet one more piece of information, which, in addition, addresses the issue of volume transmission. The authors found that <italic>extracellular</italic> levels of choline-acetyl transferase (ChAT) are actively regulated. This means that, despite ongoing extracellular cholinesterase-activity, extracellular acetylcholine is permanently resynthesized. As a consequence, acetylcholine may act over long distances from its site of release. Importantly, acetylcholine is not only synthesized and released by neurons but also by several non-neural cells. Frequently these cells express both ChAT and α7 nAChRs, and as a result, an intrinsic paracrine loop is formed [<xref ref-type="bibr" rid="CR102">102</xref>]. Examples are bronchial epithelial cells [<xref ref-type="bibr" rid="CR35">35</xref>], lymphocytes [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], human neuronal stem cells [<xref ref-type="bibr" rid="CR6">6</xref>], and astrocytes [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. As a last argument in favor of a physiological relevance of extrasynaptic α7 nAChRs, it should be mentioned that these receptors are also activated by choline, the precursor and hydrolytic split product of acetylcholine [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. In summary, extrasynaptic α7 nAChRs will be readily activated under physiological conditions.</p>
</sec>
<sec id="Sec7">
<title>Diseases in which treatment with α7 nAChR agonists could be useful</title>
<p>Since α7 nAChRs are expressed on interneurons, presynaptically on glutamatergic neurons, and on neuronal progenitor cells, the logical prediction was that α7 nAChR agonists could provide a beneficial influence on cognitive function. Consequently, the clinical testing of α7 nAChR agonists has focused on disorders with profound cognitive dysfunction (i.e., schizophrenia, Alzheimer’s disease). The fact that nicotinic α7 receptors are also strongly expressed by cells of the immune system, including those of the brain innate immune system, has often been (but not always, [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]) overlooked. With this in mind, in the following sections we will reflect on the therapeutic use of selective α7 nAChR agonists in psychiatric and neurological disorders.</p>
</sec>
<sec id="Sec8">
<title>Depression</title>
<p>Inflammation and exposure to stress are generally recognized as strong proximal factors for the development of depression symptoms [<xref ref-type="bibr" rid="CR109">109</xref>]. Many kinds of stress, but in particular those involving threat, loss, entrapment, and humiliation, lead to activation of the immune system [<xref ref-type="bibr" rid="CR109">109</xref>–<xref ref-type="bibr" rid="CR112">112</xref>]. This has been conceptualized as an anticipatory response by the innate immune system to prepare for physical injury [<xref ref-type="bibr" rid="CR113">113</xref>]. Phagocytic cells such as macrophages and microglia are essential components of the innate immune system and contribute to the host’s defense against invading microorganisms. Notably, phagocytes from patients with depression are hyper-responsive [<xref ref-type="bibr" rid="CR114">114</xref>–<xref ref-type="bibr" rid="CR116">116</xref>]. Upon activation, these cells produce cytotoxic compounds like nitric oxide and oxygen radicals [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. These reactive oxygen radicals formed during the ‘respiratory burst’ may irreversibly oxidize tetrahydrobiopterin [<xref ref-type="bibr" rid="CR119">119</xref>]. Since tetrahydrobiopterin is an essential cofactor for the production of dopamine, noradrenaline, and serotonin, the heightened activity of microglial cells may ultimately lead to a reduction in central monoamine levels (see Fig. <xref ref-type="fig" rid="Fig2">2</xref>). This could be the underlying cause of low mood and anhedonia in depression (Kalkman and Feuerbach, in preparation). As outlined above, α7 nAChRs are expressed both on macrophages and microglia, and their activation leads to anti-inflammatory effects. In particular, activation of α7 nAChRs might lead to a shift in microglia phenotype from M1-like (activated for anti-microbial activity) to M2-like (resolution, removal of debris) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR120">120</xref>], while a similar process has been described in the periphery. Stimulation of α7 nAChRs attenuates macrophage responsiveness and diminishes release of cytokines [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR66">66</xref>] and therefore will limit the negative impact of inflammation on tetrahydrobiopterin metabolism.<fig id="Fig2"><label>Fig. 2</label><caption><p>Microglia cells play a role in eradication of invading microorganisms and in removal of debris. During these processes, the cells adapt specialized phenotypes (M1 and M2-like, respectively). During the respiratory burst, labile oxygen products are formed that oxidize microbial proteins and nucleic acids, but also oxidize the essential cofactor for monoamine synthesis, tetrahydrobiopterin. Sterile neuroinflammation is a common observation in neurological and psychiatric disorders. Acetylcholine, acting via α7 nAChRs, promotes M2-polarization. As such, it reduces neuroinflammation, while promoting phagocytosis. M2-polarized microglia cells not only produce neurotrophins and anti-inflammatory cytokines, they also effectively phagocytose and catabolize Aβ. α7 nAChR agonists are expected to improve neurological and psychiatric disorders via inhibition of neuroinflammation, to restore tetrahydrobiopterin levels (improve mood symptoms) and to provide neuroprotection</p></caption><graphic id="MO2" xlink:href="18_2016_2175_Fig2_HTML"></graphic></fig></p>
<p>Activation of α7 nAChRs in the brain has been shown to activate protein kinase A (PKA) via a mechanism involving calcium-dependent activation of adenylatecyclase-1 and, consequently, an increase in cAMP levels [<xref ref-type="bibr" rid="CR61">61</xref>]. PKA is one of the kinases that increase Ser9-phosphorylation of GKS3β, which results in inhibition of the kinase activity. PKA also fosters Ser133-phosphorylation of the transcription factor CREB. Ser133-P-CREB is a substrate for GSK3β, which subsequently results in rapid catabolism of CREB and thus termination of CREB signaling. CREB competes with NFκB for binding to CREB-binding protein (CBP), and therefore limits the inflammatory NFκB signal. Activation of α7 nAChRs in the brain may thus lead to an anti-inflammatory activity. Increased PKA activity, increased Ser9-phosphorylation of GSK3β, and increased Ser133-phosphorylation of CREB have all been observed in mouse brain after chronic treatment with the α7 nAChR agonist A582941 [<xref ref-type="bibr" rid="CR62">62</xref>]. Notably, Ser9-phosphorylation of GSK3β following A582941 treatment was absent in mice with a genetic deletion of the α7 nAChR [<xref ref-type="bibr" rid="CR121">121</xref>].</p>
<p>Vagus nerve stimulation, which reduces inflammation [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR122">122</xref>], has been approved for treatment of drug-resistant depression in humans [<xref ref-type="bibr" rid="CR123">123</xref>]. In long-term naturalistic studies, significant improvements and increasing remission rates were noted in patients with refractory depression [<xref ref-type="bibr" rid="CR124">124</xref>–<xref ref-type="bibr" rid="CR126">126</xref>]. Oxytocin (reported to display antidepressant activity [<xref ref-type="bibr" rid="CR127">127</xref>]) increases the excitability of central vagal neurons in rats [<xref ref-type="bibr" rid="CR128">128</xref>] and inhibits LPS-induced release of inflammatory cytokines in healthy human subjects [<xref ref-type="bibr" rid="CR129">129</xref>]. The antidepressant activity of oxytocin could thus be a consequence of stimulation of the cholinergic anti-inflammatory pathway. In conclusion, there is accumulating evidence that α7 nAChR agonists could possess antidepressant activity, although none of the compounds that were in clinical development has been tested in this indication.</p>
</sec>
<sec id="Sec9">
<title>Schizophrenia</title>
<p>Symptoms of schizophrenia are commonly divided into three domains, namely positive symptoms (delusions, hallucinations), negative symptoms (social withdrawal, anhedonia), and cognitive deficits (learning and memory deficits, alogia). A history of maternal and prenatal infections, prior hospitalization for severe infection, and autoimmune comorbidity represent major risk factors for schizophrenia [<xref ref-type="bibr" rid="CR130">130</xref>]. These conditions, which are linked to the elevation of pro-inflammatory cytokines has led to the formulation of the “prenatal cytokine hypothesis” [<xref ref-type="bibr" rid="CR131">131</xref>]. This hypothesis proposes that early alterations in the peripheral and central innate immune system disrupt normal development and maturation of neuronal systems during the juvenile and early adult stages of life, affecting processes such as myelination, synaptic pruning, and neuronal modeling [<xref ref-type="bibr" rid="CR131">131</xref>]. Results from genetic studies are consistent with such a process, as confirmed genetic risk factors for schizophrenia include mutations in genes involved in immune function (e.g., HLA-C and HLA-DRA) and synaptic pruning [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR133">133</xref>]. The first episode of psychosis is often associated with microglia activation [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>], elevated levels of pro-inflammatory cytokines in the CSF [<xref ref-type="bibr" rid="CR136">136</xref>–<xref ref-type="bibr" rid="CR138">138</xref>], and a significant loss in white matter volume (reviewed in [<xref ref-type="bibr" rid="CR136">136</xref>]). It is assumed that cytokines, chemokines, prostaglandins, and reactive oxygen products released by activated microglia generate a toxic milieu for oligodendrocytes (leading to white matter loss) and neurites (gray matter loss) [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]. The severity of negative symptoms correlates with the diminution of white matter [<xref ref-type="bibr" rid="CR130">130</xref>].</p>
<p>The impetus to develop α7 nAChR agonists was based on two sets of clinical information. First, the early literature reported extremely high values for the prevalence of smoking in schizophrenia patients (see [<xref ref-type="bibr" rid="CR141">141</xref>]). This information was supplemented by data from radioligand binding experiments investigating brain tissue of deceased schizophrenia patients (for summary see [<xref ref-type="bibr" rid="CR100">100</xref>]). Using [<sup>125</sup>I]-α-bungarotoxin (α-btx) as radioligand, a <italic>reduction</italic> in labeling of the α7 nAChR was found in the dentate gyrus [<xref ref-type="bibr" rid="CR142">142</xref>], the reticular nucleus of the thalamus [<xref ref-type="bibr" rid="CR143">143</xref>], the frontal cortex [<xref ref-type="bibr" rid="CR144">144</xref>], and the cingulate cortex [<xref ref-type="bibr" rid="CR1">1</xref>]. A vast body of genetic literature supports the contention that the functionality of the α7 nAChR in schizophrenia is diminished. CHRNA7, the gene encoding the α7 nAChR, is located on 15q14, a chromosomal area that is linked to genetic transmission of schizophrenia [<xref ref-type="bibr" rid="CR145">145</xref>]. This area is also subject to deletion copy number variations (CNVs,) [<xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR147">147</xref>]. Decreases in α-btx binding observed in schizophrenia patients could be due to an increased expression and insertion of dupα7, since heteromeric dupα7/α7 nAChRs do not bind this radioligand [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR148">148</xref>]. Notably, decreased α-btx binding is unlikely to be explained by differences in smoking behavior [<xref ref-type="bibr" rid="CR1">1</xref>]. Polymorphisms in the CHRNA7 promoter that decrease gene-transcription are also associated with schizophrenia [<xref ref-type="bibr" rid="CR149">149</xref>]. A 2 bp deletion allele in CHRFAM7A is frequent in Caucasians (42 %) and less in African-Americans (14 %) [<xref ref-type="bibr" rid="CR150">150</xref>]. This 2 bp deletion form of CHRFAM7A is an even stronger inhibitor of α7 nAChR than wild-type CHRFAM7A and consistent with this, several studies support an association of the 2 bp deletion in the CHRFAM7A gene with schizophrenia and bipolar disorder (summarized by Sinkus et al. [<xref ref-type="bibr" rid="CR150">150</xref>]). Finally, CNVs occur in the CHRNA7 and in CHRFAM7A, and deletions were strongly associated with schizophrenia. Interestingly, this was especially the case when the CHRNA7 was deleted, while CHRFAM7A was present [<xref ref-type="bibr" rid="CR150">150</xref>].</p>
<p>The pathophysiological consequence of the diminished functionality was mainly sought in the cognitive domain. The prediction that α7 nAChR agonists would improve cognition in schizophrenia was tested clinically with a series of development compounds (for a recent reviews, see [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR152">152</xref>]). Since the nicotine α7 receptor and the 5HT3 receptor are phylogenetically very similar, several developmental α7 nAChR agonists lack selectivity and block the 5HT3 receptor concomitantly [<xref ref-type="bibr" rid="CR108">108</xref>]. Encenicline (EVP6124), which is a mixed α7 nAChR agonist/5HT3 antagonist, showed significant clinical improvement on PANSS cognitive impairment domain and also for the PANSS negative scale [<xref ref-type="bibr" rid="CR153">153</xref>]. Another mixed α7 nAChR agonist and 5HT3 antagonist tropisetron significantly reduced PANSS total and the negative symptom subscale with increasing treatment time [<xref ref-type="bibr" rid="CR154">154</xref>]. Further, a mixed α7 agonist/5HT3 antagonist RG3487 (also known as MEM3454), was reported to improve negative symptoms and depression ratings [<xref ref-type="bibr" rid="CR155">155</xref>]. It remains unclear if the beneficial effect on negative symptom ratings is due to α7 nAChR activation or to 5HT3 blockade, as both a selective α7 nAChR agonist (TC-5619) and a selective 5HT3 antagonist (ondansetron) improved negative symptoms [<xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR157">157</xref>]. DMXB-A (GTS-21) [<xref ref-type="bibr" rid="CR158">158</xref>], a α7 nAChR agonist with additional inhibitory activity at α4β2 nAChRs [<xref ref-type="bibr" rid="CR159">159</xref>], improved alogia and anhedonia ratings in the scale for assessment of negative symptoms. Remarkably, α7 nAChR-positive allosteric modulators (galantamine, galantamine plus choline, and JNJ39393406) were completely inactive [<xref ref-type="bibr" rid="CR100">100</xref>]. Taken together, these data show that α7 nAChR activation did not improve positive symptoms, whereas a beneficial effect against negative symptoms was observed repeatedly. The clinical evidence that α7 nAChR activation leads to improvement of cognitive dysfunction in schizophrenia still remains somewhat equivocal [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR160">160</xref>], although the data for encenicline are encouraging [<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. It is noteworthy that the clinical development of several mixed nAChR α7 agonist/5HT3 antagonist compounds (e.g., RG3487, tropisetron) in schizophrenia has been halted [<xref ref-type="bibr" rid="CR152">152</xref>]. This may be related to side effects associated with 5HT3 receptor blockade (e.g., constipation, arrhythmias) (see [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR162">162</xref>, <xref ref-type="bibr" rid="CR163">163</xref>]). Currently, three α7 nAChR agonists remain in clinical development (AQW051, encenicline, and GTS-21) [<xref ref-type="bibr" rid="CR152">152</xref>].</p>
<p>The observation that nAChR α7 agonists improve negative symptoms is remarkable. It can be speculated that stimulation of nAChRs α7 counteracts microglia activation, such that white and gray matters are exposed less to the toxic microglia products. In this respect it is noteworthy that minocycline, a compound which suppresses microglia activation, also specifically improved negative symptoms (for review see [<xref ref-type="bibr" rid="CR164">164</xref>]). Negative symptoms, like symptoms of melancholic depression, might reflect distinct behavioral consequences of central inflammation. However, it could be that negative symptoms are not distinct and in fact reflect aspects of melancholic depression, or that rating scales for negative symptoms do not discriminate between depression symptoms and negative symptoms [<xref ref-type="bibr" rid="CR155">155</xref>]. Since microglia activation occurs early in the disease process (i.e., during, or even before, the first period of psychosis), early intervention with compounds that limit microglia activation (nAChR α7 agonists, minocycline) might be appropriate.</p>
</sec>
<sec id="Sec10">
<title>Bipolar disorder</title>
<p>The cardinal features of bipolar disorder are recurrent episodes of depression and hypomania, whereas the latter includes euphoric or irritable mood, mental and behavioral over-activity, as well as decreased need for sleep and involvement in risky activities [<xref ref-type="bibr" rid="CR165">165</xref>]. As for major depressive disorder, diseases and habits that are associated with peripheral inflammation (diabetes, obesity, cardiovascular disease, smoking, and alcohol abuse) are recognized risk factors for bipolar disorder (reviewed in [<xref ref-type="bibr" rid="CR166">166</xref>–<xref ref-type="bibr" rid="CR168">168</xref>]). And in further similarity to major depression, childhood trauma is a strong predictor for appearance of bipolar disorder later in life [<xref ref-type="bibr" rid="CR169">169</xref>]. Increases in serum levels of inflammation markers have been observed during manic, depressed and even euthymic phases [<xref ref-type="bibr" rid="CR170">170</xref>–<xref ref-type="bibr" rid="CR173">173</xref>]. Bipolar disorder shares genetic risk loci with schizophrenia and with major depression [<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR174">174</xref>]. There is evidence for microglia activation in the brain of bipolar disorder patients: first, higher levels of IL1β, IL1R, MYD88, and iNOS have been found in a post-mortem study in the frontal cortex [<xref ref-type="bibr" rid="CR175">175</xref>]. Second, microglia-derived inflammation markers MCP1 and YKL40 were increased in CSF [<xref ref-type="bibr" rid="CR176">176</xref>], and third, microglia activation was detected by PK11195 imaging [<xref ref-type="bibr" rid="CR177">177</xref>]. The inflammatory milieu in the brain is probably responsible for atrophy, volumetric changes, cognitive decline, and symptom worsening [<xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR175">175</xref>]. The same genetic polymorphisms, copy number variations and alteration in the pseudo-gene CHRFAM7A, which are presumed to diminish the functionality of the nAChR α7 receptor in schizophrenia, have also been detected in bipolar disorder [<xref ref-type="bibr" rid="CR161">161</xref>, <xref ref-type="bibr" rid="CR178">178</xref>].</p>
<p>The neurodevelopmental consequences of diminished α7 nAChR signaling may be inferred from studying CHRNA7 knockout mice. It has been reported that nicotine administration to these animals led to a longer period of elevated extracellular dopamine levels in the nucleus accumbens than in control mice [<xref ref-type="bibr" rid="CR179">179</xref>]. Excessive dopamine signaling via D2 receptors in the striatum causes an activation of GSK3β via a multiprotein complex involving the D2 receptor, β-arrestin, Akt, GSK3β, and PP2A [<xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR181">181</xref>], while active GSK3β results in diminished long-term potentiation (LTP) [<xref ref-type="bibr" rid="CR182">182</xref>–<xref ref-type="bibr" rid="CR184">184</xref>]. Unexpected rewarding outcomes result in dopamine release in the striatum, whereas unpredicted negative outcomes result in a strong reduction in dopamine output [<xref ref-type="bibr" rid="CR185">185</xref>]. Such a dopamine “dip” improves avoidance learning (via D2 receptor hypo-stimulation) by decreasing GSK3β activity, and thus promoting LTP. In contrast, hyper-stimulation of D2 receptors, and activation of GSK3β, both result in a diminished learning from incorrect reward predictions. If we assume that the α7-p85-Akt-GSK3β pathway is activated in striatal neurons (as it is in immune cells), dysfunction of the α7 nAChR would result in reduced inhibitory GSK3β-phosphorylation, in poorer learning from unrewarding conditions, and eventually in more (i.e., less suppressed) risk-taking behavior. Taken together, dysfunction of the α7 nAChR would increase both depression-risk and hypomania symptoms. The prediction that selective α7 nAChR agonists might counteract these symptoms remains to be tested.</p>
</sec>
<sec id="Sec11">
<title>Autism spectrum disorder</title>
<p>Autism is a general term for a group of neurodevelopmental disorders characterized by difficulties in social interaction, verbal and non-verbal communication, and repetitive behaviors. Several distinct subtypes have been identified, and these are often combined under the umbrella diagnosis “autism spectrum disorder” (ASD). Certain genetic copy number variations, which can be either inherited or occur de novo, exert a profound effect on brain development and lead to syndromes that fit the ASD diagnosis. The 15q13.3 microdeletion syndrome is such an example. Gillentine and Schaaf [<xref ref-type="bibr" rid="CR147">147</xref>] collected all published cases of heterozygous 15q13.3 deletions and calculated that nearly half of them displayed cognitive deficits, while seizures and symptoms of ASD were noted in 26 and 21 % of these cases, respectively. It is not clarified by which mechanism heterozygosity for the α7 nAChR could lead to ASD. It is known, however, that the α7 nAChR is essential for the formation of NMDA synapses [<xref ref-type="bibr" rid="CR86">86</xref>], and that the absence of functional α7 nAChRs results in perturbation of NMDA neurotransmission at glutamatergic synapses [<xref ref-type="bibr" rid="CR186">186</xref>]. The EphB2 receptor is involved in the process by which α7 nAChRs enhance formation of NMDA synapses [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR187">187</xref>] and, interestingly, also dysfunction of the EphB2-receptor has been recognized as a risk factor for autism spectrum disorder [<xref ref-type="bibr" rid="CR188">188</xref>].</p>
<p>Rett syndrome is another distinct genetic form of autism. In the majority of cases, Rett syndrome is caused by a mutation in the MeCP2 gene; the functional consequence of this mutation is a severe reduction in the expression of α7 nAChRs [<xref ref-type="bibr" rid="CR91">91</xref>]. Yasui and colleagues have therefore proposed to use α7 nAChR agonists for the treatment of Rett syndrome.</p>
<p>Although the pathology seen after partial deletion or dysfunction of the α7 nAChR provides support for its physiological role, it also creates a dilemma for pharmacotherapy with α7 agonists. Such compounds can only work when the receptor is present and functional. A study by Le Pichon and colleagues exemplifies this [<xref ref-type="bibr" rid="CR189">189</xref>]. The authors created lymphoblastoid cell lines from a patient with a <italic>homozygous</italic> 15q13.3 microdeletion, his heterozygous parents, and from several further family members and age-matched controls. The lymphoblast cells were treated with lipopolysaccharide, which provoked the expected increase in TNFα release. TNFα release was suppressed by nicotine (which in turn could be blocked by the α7 nAChR antagonist α-btx) in all control and hemizygous deletion cell lines, but notably <italic>not</italic> in lymphoblasts from the index patient [<xref ref-type="bibr" rid="CR189">189</xref>]. Patients with a strongly dysfunctional or absent α7 nAChR will not benefit from a α7 nAChRs agonist. It is reasonable to assume that cases of moderate hypoactivity of the α7 nAChR will exist among the wide spectrum of autism disorders, but the challenge will be to identify a biomarker to enable their selection. The current clinical evidence for a therapeutic effect of an increase in cholinergic signaling in ASD is quite limited. It is based on a few open label studies, case reports and a single small-size double-blind augmentation study with a cholinesterase-inhibitor [<xref ref-type="bibr" rid="CR190">190</xref>].</p>
<p>In a subset of autism patients, there is evidence for an increase in allergic inflammation [<xref ref-type="bibr" rid="CR191">191</xref>] and for mast cell activation [<xref ref-type="bibr" rid="CR192">192</xref>]. These observations hint to an increased T<sub>H</sub>2 polarization (perhaps owing to a helminth infection). An infection with a helminth would skew the differentiation of helper T-cell towards the T<sub>H</sub>2 phenotype. IL4 and IL5, cytokines produced by T<sub>H</sub>2 cells [<xref ref-type="bibr" rid="CR193">193</xref>], promote macrophage/microglia M2A polarization and mast cell activation [<xref ref-type="bibr" rid="CR194">194</xref>–<xref ref-type="bibr" rid="CR196">196</xref>]. Indeed, Gupta et al. [<xref ref-type="bibr" rid="CR197">197</xref>], recently reported that the expression pattern of microglia genes in autism cases was characteristic for an increased M2A phenotype. Treatment with α7-agonists is expected to further increase M2 polarization, and thus could accentuate the autism-phenotype. According to this line of reasoning, the treatment with α7 nAChR agonists might be contra-indicated in at least some forms of autism spectrum disorder.</p>
</sec>
<sec id="Sec12">
<title>Multiple sclerosis</title>
<p>Neuroinflammation represents a key aspect of the neurological disorders that will be discussed in this and following sections. Multiple sclerosis (MS) is an autoimmune disease that affects axonal nerve transmission in peripheral, lumbal, and central nerves, which as first symptoms often results in motor and sensory problems. Depression is a common comorbidity [<xref ref-type="bibr" rid="CR198">198</xref>]. The precise sequence of events that leads to MS in patients is not known [<xref ref-type="bibr" rid="CR199">199</xref>], but activation of lymphocytes, macrophages, dendritic cells, and microglia are known to occur early in the disease [<xref ref-type="bibr" rid="CR200">200</xref>]. α7 nAChR activation can lead to inhibition of lymphocyte proliferation [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR201">201</xref>] and to inhibition of macrophage and microglia activation [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Stimulation of α7 nAChR on endothelial cells furthermore limits the extravasation of leukocytes during inflammation [<xref ref-type="bibr" rid="CR31">31</xref>], although it is not known if this is also true for the blood–brain barrier. Together, these findings suggest that α7 nAChR agonists might be therapeutically useful in multiple sclerosis. Indeed, nicotine was shown to inhibit experimental MS in rodents [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR201">201</xref>], but to our knowledge, selective α7 nAChR agonists remain to be investigated in human MS.</p>
</sec>
<sec id="Sec13">
<title>Parkinson’s disease</title>
<p>The motor symptoms of Parkinson’s disease (PD) are ascribed to degeneration of dopaminergic neurons in the <italic>substantia nigra pars compacta</italic>. Other important symptoms are anxiety and depression, as well as memory loss, confusion, and dementia. In this respect, it is noteworthy that not only dopamine neurons perish but also the cholinergic system. Degeneration of the basal forebrain cholinergic system occurs early in the disease process and precedes the dementia symptoms [<xref ref-type="bibr" rid="CR202">202</xref>, <xref ref-type="bibr" rid="CR203">203</xref>]. In fact, in PD-dementia the levels of cerebral ChAT are reduced to levels below those seen in Alzheimer’s disease [<xref ref-type="bibr" rid="CR204">204</xref>], whereas cholinesterase inhibition improves dementia in Parkinson’s disease [<xref ref-type="bibr" rid="CR205">205</xref>].</p>
<p>A large number of epidemiological studies (for a recent summary see [<xref ref-type="bibr" rid="CR120">120</xref>]) have consistently shown that smoking is associated with a lower incidence of PD. Data from preclinical models of Parkinson’s disease indicate that nicotine and selective α7 nAChR agonists reduce microglia activation and neuroinflammation, and prevent <italic>nigro</italic>-<italic>striatal</italic> dopamine-neuronal loss [<xref ref-type="bibr" rid="CR206">206</xref>, <xref ref-type="bibr" rid="CR207">207</xref>]. α7 nAChRs expressed on astrocytes may also contribute to the neuroprotective effect, since activation of these receptors suppressed astroglial apoptosis induced by oxidative stress and preserved neurotrophic factor supply by glial cells [<xref ref-type="bibr" rid="CR208">208</xref>]. An alternative suggestion is that nicotine reduces PD symptoms owing to its stimulant effect on <italic>nigro</italic>-<italic>striatal</italic> dopamine release. This nicotine-induced dopamine release is mediated primarily via α6β2-containing receptors localized on dopaminergic neurons. These neurons are particularly vulnerable to damage and in models of <italic>nigro</italic>-<italic>striatal</italic> damage, the α6β2-receptor numbers are significantly reduced [<xref ref-type="bibr" rid="CR209">209</xref>]. For this reason, it is rather unlikely that the indirect dopamine release induced by nicotine acting on α6β2 receptors plays a significant role in the positive effect of smoking in PD. Post-mortem studies of brains from patients with Parkinson’s disease provide convincing evidence for neuroinflammation in the <italic>pars compacta</italic>, with increases in neurotoxic cytokines, microglia activation, and lymphocyte infiltration (reviewed by Hirsch and Hunot [<xref ref-type="bibr" rid="CR210">210</xref>]).</p>
<p>Depression occurs in about 35 % of PD-patients [<xref ref-type="bibr" rid="CR211">211</xref>] and might develop in the premotor stage of the disease [<xref ref-type="bibr" rid="CR211">211</xref>, <xref ref-type="bibr" rid="CR212">212</xref>]. Consistent with theories about microglia activation as contributor to depression [<xref ref-type="bibr" rid="CR213">213</xref>, <xref ref-type="bibr" rid="CR214">214</xref>], depressive symptoms may be considered as an early indicator of Parkinson’s disease. The protective effect that smoking exerts on PD could thus relate to α7 nAChR-mediated anti-inflammatory activity of nicotine [<xref ref-type="bibr" rid="CR11">11</xref>]. This would imply that selective α7 nAChR agonists could be effective as prophylactic treatment for Parkinson’s disease. In this respect, it is worthwhile to mention that in MPTP-treated laboratory animals, the density of α7 nAChR increases (which is in contrast to α6β2-containing nAChRs, see above) [<xref ref-type="bibr" rid="CR215">215</xref>]. The α7 nAChR agonist AQW051 [<xref ref-type="bibr" rid="CR216">216</xref>] has been tested in patients with established Parkinson’s disease (ClinicalTrials.gov), but results remain to be published.</p>
</sec>
<sec id="Sec14">
<title>Alzheimer’s disease</title>
<p>One of the functions of microglia is to remove debris [<xref ref-type="bibr" rid="CR217">217</xref>]. Microglia cells phagocytose and subsequently degrade Aβ, and thereby promote the removal of Aβ from the brain [<xref ref-type="bibr" rid="CR218">218</xref>]. As mentioned before, microglia cells assume different phenotypes. With aging, microglia shift their morphology to a pro-inflammatory state and presumably lose their ability to phagocytose [<xref ref-type="bibr" rid="CR219">219</xref>]. Activation of α7 nAChR expressed on microglia alters the phenotype and promotes phagocytosis and metabolism of Aβ [<xref ref-type="bibr" rid="CR12">12</xref>]. Based on these data, one would expect that nicotine (smoking) and cholinesterase inhibitors would diminish Aβ load and improve Alzheimer disease. In transgenic animals, overexpressing Aβ beneficial effects of nicotine or ChE-I were indeed observed, while knock out of the α7 nAChR worsened pathology [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR220">220</xref>]. In patients with Alzheimer’s disease, cholinesterase inhibitors limit the cognitive deficits early in the course of the disease, but dosing and efficacy are limited by cholinergic (in particular muscarinic) side effects. For this reason, it is expected that α7 nAChR agonists might reach a similar therapeutic efficacy, but with less side effects. In a recent meta-analysis of prospective cohort studies investigating the effect of smoking on dementia and Alzheimer’s disease, smoking <italic>increased</italic> risk for dementia and AD [<xref ref-type="bibr" rid="CR221">221</xref>]. This meta-analysis study included 37 studies with a total of almost 1 million patients and the statistical power was sufficient to investigate the influence of age. The increase in dementia risk was observed in the age group between 65 and 75, whereas the interpretation of results from patients older than 75 was hampered by a survival effect. Importantly, the increase in dementia or AD risk was not significant for smokers <italic>under</italic> 65 [<xref ref-type="bibr" rid="CR221">221</xref>]. This result is clearly different from Parkinson’s disease, where smoking tendentially caused more benefit than harm [<xref ref-type="bibr" rid="CR222">222</xref>]. Why would this be? The answer may lie in the special interaction of Aβ with α7 nAChRs. Parri et al. [<xref ref-type="bibr" rid="CR223">223</xref>] have recently reviewed this in great detail. The fact that Aβ binds to α7 nAChRs has been observed and confirmed in numerous experimental settings, including post-mortem AD brain; however, it is unclear if this interaction results in inhibition or in stimulation of the receptor, and whether this interaction is reversible by agonists and antagonists. An intra-subunit allosteric binding pocket within the transmembrane domain of the α7 nAChR has been described as mechanism for non-competitive antagonism by Aβ (summarized by Parri et al. [<xref ref-type="bibr" rid="CR223">223</xref>]). A further complication with relevance to AD pathology is the observation that cholinergic neurons in the basal forebrain express a heteromeric α7β2 isoform [<xref ref-type="bibr" rid="CR224">224</xref>, <xref ref-type="bibr" rid="CR225">225</xref>]. Liu et al. [<xref ref-type="bibr" rid="CR224">224</xref>] have reported that the α7β2 receptor is particularly sensitive to Aβ, since concentrations as low as 1 nM inhibited the functional responses to choline. They furthermore noted that inhibition was strongest with Aβ in its oligomeric form, followed by fibrillar Aβ, whereas monomeric Aβ was inactive. It is not clear why blockade of the α7β2 receptor is neurotoxic to cholinergic neurons, and if microglia cells from basal forebrain structures express this heteromeric nicotinic receptor. Nevertheless, one can begin to sketch a positive feedback process where aging causes polarization of microglia towards a phenotype that is less effective in phagocytosing and degrading Aβ. An overload of oligomeric Aβ in the extracellular space will block the α7β2 nicotinic receptor on basal forebrain cholinergic neurons, and these die as a consequence. Less acetylcholine leads to a reduction in α7 nAChR stimulation of microglia cells, which results in further loss of their phagocytic capacity. Diminished clearance of Aβ ultimately leads to extracellular precipitates, which presumably are a further trigger to microglia recruitment, inflammatory processes, and further toxicity to cholinergic neurons (see Fig. <xref ref-type="fig" rid="Fig3">3</xref>). In this process, an early intervention with nicotine, cholinesterase inhibitors, and in principle, α7 nAChR agonists may delay the start of the vicious circle. However, later in the process the availability of α7 nAChRs will be reduced by the negative interaction with the accumulating oligomeric Aβ. This would explain why the toxic effects of smoking become dominant over the neuroprotective effects in Alzheimer’s disease, but not (or less) in Parkinson’s disease. If the above-sketched vicious circle is correct, treatment with selective α7 nAChR agonists would be useful as prophylaxis, but less so for treatment of established severe AD-dementia.<fig id="Fig3"><label>Fig. 3</label><caption><p>During aging the polarization of microglia gradually shifts towards the M1 phenotype. Diminution of M2 polarization presumably has negative consequences for Aβ catabolism. When extracellular Aβ levels increase, several positive feedback loops are triggered that ultimately lead to the demise of cholinergic neurons. Activation of α7 nAChRs counteracts the loss of the M2 phenotype. α7 nAChR agonists may furthermore compete with Aβ at (mitochondrial?) nicotinic α7β2 receptors. Treatment with α7 nAChR agonists might therefore delay the demise of cholinergic neurons, and thus delay the onset of dementia</p></caption><graphic id="MO3" xlink:href="18_2016_2175_Fig3_HTML"></graphic></fig></p>
</sec>
<sec id="Sec15">
<title>Discussion</title>
<p>From a historical perspective, selective α7 nAChR agonists have been targeted for cognitive deficits associated with schizophrenia (for recent reviews see [<xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR226">226</xref>]) and dementia in Alzheimer’s disease [<xref ref-type="bibr" rid="CR227">227</xref>, <xref ref-type="bibr" rid="CR228">228</xref>]. Where investigated, the dose–response relationships for the pro-cognitive effects of α7 nAChR agonists usually display an inverted U-shape, indicating that higher doses are less effective than certain lower doses [<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR229">229</xref>–<xref ref-type="bibr" rid="CR232">232</xref>]. Although the exact mechanism behind this profile remains speculative, it has been frequently noted that high concentrations of agonist cause receptor desensitization and suppression of functional responses [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR233">233</xref>]. For instance, in in vitro experiments in oocytes, high concentrations of α7 nAChR agonists desensitized the receptor and blocked the calcium influx to the endogenous agonist acetylcholine [<xref ref-type="bibr" rid="CR234">234</xref>]. Similar inhibitory effects on calcium influx were observed with synthetic α7 nAChR agonists at high concentrations [<xref ref-type="bibr" rid="CR235">235</xref>]. Remarkably though, at lower concentrations a number of α7 nAChR agonists actually may potentiate the acetylcholine-induced response [<xref ref-type="bibr" rid="CR236">236</xref>]. Estimations of brain levels at which α7 nAChR agonists evoke cognition-enhancing effects are in the range where they potentiate the acetylcholine-induced calcium influx in oocytes. It is therefore reasonable to assume that the pro-cognitive effect of α7 nAChR agonists is due to an enhancement of the acetylcholine-evoked response (known as the “co-agonist hypothesis,” see [<xref ref-type="bibr" rid="CR236">236</xref>, <xref ref-type="bibr" rid="CR237">237</xref>]). This assumption is supported by preclinical data demonstrating an additive pro-cognitive effect of donepezil and the α7 nAChR agonist encenicline [<xref ref-type="bibr" rid="CR236">236</xref>]. Although not yet reported, a similar co-agonist effect may occur at α7 receptors expressed by immune cells. If true, this would imply that low doses of a α7 nAChR agonist would be sufficient to enhance the anti-inflammatory response to the endogenous agonists (choline and/or acetylcholine).</p>
<p>In reviews dealing with potential indications of selective α7 nAChR agonists, the anti-inflammatory activity has never taken central stage (at least up to recently, see [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]). The role that inflammation plays in the pathophysiology of psychiatric disorders is, however, well recognized [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR176">176</xref>, <xref ref-type="bibr" rid="CR238">238</xref>]. In the current review, we argue that several alternative indications for α7 agonists may be delineated from their effect on inflammation. Treatment with α7 nAChRs agonist may result in inhibition of the pro-inflammatory enzyme, GSK3β. In this respect, the treatment with α7-agonists resembles lithium treatment. This similarity may hold true not only for an indication like bipolar disorder (improvement in both manic and depressive symptoms) but also for suicide and neurological disorders. Suicide is a major cause of death in depression, bipolar disorder, and schizophrenia. Clinical data have accumulated which indicate that inflammation and microglia M1-polarization contribute to the pathophysiology of suicide <italic>independent</italic> from the underlying psychiatric disease [<xref ref-type="bibr" rid="CR239">239</xref>–<xref ref-type="bibr" rid="CR242">242</xref>]. Diverse pro-inflammatory mechanisms such as autoimmunity, neurotropic pathogens, stress, or traumatic brain injury have been documented in suicidal patients [<xref ref-type="bibr" rid="CR243">243</xref>]. Since α7 nAChR stimulation in immune cells can result in GSK3β inhibition, and since the GSK3-inhibitor, lithium [<xref ref-type="bibr" rid="CR244">244</xref>], is a recognized anti-inflammatory [<xref ref-type="bibr" rid="CR245">245</xref>] <italic>and</italic> anti-suicidal compound [<xref ref-type="bibr" rid="CR246">246</xref>, <xref ref-type="bibr" rid="CR247">247</xref>], one may propose the use of nicotine α7-agonists for prevention of suicide. Chronic treatment with lithium by virtue of its GSK3β inhibitory effect also ameliorated the disease processes in preclinical models of multiple sclerosis [<xref ref-type="bibr" rid="CR248">248</xref>], Alzheimer [<xref ref-type="bibr" rid="CR249">249</xref>–<xref ref-type="bibr" rid="CR251">251</xref>], and Parkinson’s disease [<xref ref-type="bibr" rid="CR252">252</xref>–<xref ref-type="bibr" rid="CR254">254</xref>]. It should be noted though that GSK3β inhibition by lithium in these models is just a symptomatic treatment and does not stop the underlying pathological processes. Consequently, once the pharmacotherapy is interrupted, the disease is likely to return. Nevertheless, treatment with a α7 nAChR agonist might constitute a safe alternative to lithium and one could propose the use of α7 nAChR agonists for these neurological disorders.</p>
<p>In contrast to lithium treatment, the beneficial effect of α7 nAChR stimulation is lost when the receptor is defective (or missing all together). An example was presented in the autism section, and also in late-stage Alzheimer’s disease, the nicotine receptor owing to the interaction with the β-amyloid protein may become severely dysfunctional. One potential explanation for the lack of robust effects of α7 nAChR agonists on cognitive function in schizophrenia is the rapid desensitization of α7 nAChRs. This is a general concern and applies to any α7 nAChR agonist indication. A simple biomarker test for quantification of α7 nAChR stimulation on an inflammation read-out would thus be highly desirable. Perhaps the receptor desensitization of α7 nAChRs may be less of an issue for inflammation-related indications. In this context, it is remarkable that basically all α7 agonists were effective against negative symptoms of schizophrenia (while effects on cognition were equivocal). We would also expect that the beneficial effects of smoking and cholinesterase-inhibitor-treatment would be absent if α7 nAChRs would be desensitized for most of the time. However, it must be admitted that a thorough investigation of the concentration/response relationship for the anti-inflammatory effect of any of the selective α7 nAChR agonists remains to be determined.</p>
<p>Since epidemiological data suggest that smoking exerts a protective effect in Parkinson’s disease, α7 nAChR agonists might be a preferable alternative to cholinesterase inhibition and smoking. Registration studies for prophylactic indications such as in Parkinson’s or Alzheimer’s disease are however difficult, long lasting, and expensive, and it is unlikely that companies will invest in these indications without the opportunity for registration in an acute disorder. What could be the pioneer indication for α7 nAChR agonists? Based on clinical information from vagus nerve stimulation treatment, depression would be a logical choice. Unfortunately, depression studies generally suffer from a high placebo response, making also the indication ‘depression’ less attractive.</p>
<p>We currently favor <sc>l</sc>-DOPA-induced dyskinesia as possible ‘pioneer indication.’ It has been published that two chemically distinct α7 nAChR agonists, ABT-107 and AQW051, suppress <sc>l</sc>-DOPA-induced dyskinesias in (MPTP-treated) Parkinsonian monkeys [<xref ref-type="bibr" rid="CR255">255</xref>, <xref ref-type="bibr" rid="CR256">256</xref>]. The precise mechanism by which this response is brought about remains unknown; however, again it may involve GSK3 inhibition, since low-dose lithium was also recently shown to be active in a similar Parkinson model in mice [<xref ref-type="bibr" rid="CR254">254</xref>]. The beneficial effect of α7 nAChR agonists may involve attenuation of MPTP-induced neuroinflammation and protection dopamine neurons in the substantia nigra pars compacta [<xref ref-type="bibr" rid="CR206">206</xref>]. Thus, efficacy for α7 nAChR agonists in clinical trials of <sc>l</sc>-DOPA-induced dyskinesias could serve as a clinical entry point to pave the way for indications where longer treatment regimens are warranted.</p>
</sec>
</body>
<back>
<ack>
<p>The authors would like to thank Dr. D. Shimshek for critically reading an earlier version of the manuscript and Dr. C. Parker for his support with the final version of the review.</p>
</ack>
<notes notes-type="conflict-interest">
<title>Compliance with ethical standards</title>
<sec id="FPar1">
<title>Conflict of interest</title>
<p>All authors declare that this review was prepared without external support. Hans O. Kalkman has no conflicts of interest. Dominik Feuerbach is an employee of Novartis.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marutle</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Court</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Piggott</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nordberg</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia</article-title>
<source/>J Chem Neuroanat
          <year>2001</year>
<volume>22</volume>
<fpage>115</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1016/S0891-0618(01)00117-X</pub-id>
<pub-id pub-id-type="pmid">11470559</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hurst</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rollema</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Nicotinic acetylcholine receptors: from basic science to therapeutics</article-title>
<source/>Pharmacol Ther
          <year>2013</year>
<volume>137</volume>
<fpage>22</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.08.012</pub-id>
<pub-id pub-id-type="pmid">22925690</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dineley</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Pandya</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Yakel</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Nicotinic ACh receptors as therapeutic targets in CNS disorders</article-title>
<source/>Trends Pharmacol Sci
          <year>2015</year>
<volume>36</volume>
<fpage>96</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1016/j.tips.2014.12.002</pub-id>
<pub-id pub-id-type="pmid">25639674</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>John</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shelukhina</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Yanagawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Deuchars</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Functional alpha7 nicotinic receptors are expressed on immature granule cells of the postnatal dentate gyrus</article-title>
<source/>Brain Res
          <year>2015</year>
<volume>1601</volume>
<fpage>15</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2014.12.041</pub-id>
<pub-id pub-id-type="pmid">25553616</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>JX</given-names>
</name>
<name>
<surname>Yakel</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Functional alpha7 nicotinic ACh receptors on astrocytes in rat hippocampal CA1 slices</article-title>
<source/>J Mol Neurosci
          <year>2012</year>
<volume>48</volume>
<fpage>14</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-012-9719-3</pub-id>
<pub-id pub-id-type="pmid">22351110</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vijayaraghavan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Karami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aeinehband</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Behbahani</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Grandien</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ekdahl</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Lindblom</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Piehl</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Darreh-Shori</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Regulated extracellular choline acetyltransferase activity—the plausible missing link of the distant action of acetylcholine in the cholinergic anti-inflammatory pathway</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e65936</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0065936</pub-id>
<pub-id pub-id-type="pmid">23840379</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinkus</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Graw</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Lester</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The human CHRNA7 and CHRFAM7A genes: a review of the genetics, regulation, and function</article-title>
<source/>Neuropharmacology
          <year>2015</year>
<volume>96</volume>
<fpage>274</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.02.006</pub-id>
<pub-id pub-id-type="pmid">25701707</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shytle</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Townsend</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Vendrame</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ehrhart</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Silver</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Sanberg</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors</article-title>
<source/>J Neurochem
          <year>2004</year>
<volume>89</volume>
<fpage>337</fpage>
<lpage>343</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2004.02347.x</pub-id>
<pub-id pub-id-type="pmid">15056277</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Simone</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ajmone-Cat</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Carnevale</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Minghetti</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures</article-title>
<source/>J Neuroinflamm
          <year>2005</year>
<volume>2</volume>
<fpage>4</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-2-4</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hide</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Matsubara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hama</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miyano</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Andra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matsubayashi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kohsaka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakata</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role</article-title>
<source/>J Neurosci Res
          <year>2006</year>
<volume>83</volume>
<fpage>1461</fpage>
<lpage>1470</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.20850</pub-id>
<pub-id pub-id-type="pmid">16652343</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>YW</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>BK</given-names>
</name>
</person-group>
<article-title>Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action</article-title>
<source/>Eur J Neurosci
          <year>2007</year>
<volume>26</volume>
<fpage>79</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2007.05636.x</pub-id>
<pub-id pub-id-type="pmid">17581257</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kitamura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Saeki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Terada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kagitani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kitamura</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fujikawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Maelicke</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tomimoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Taniguchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shimohama</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors</article-title>
<source/>J Biol Chem
          <year>2010</year>
<volume>285</volume>
<fpage>40180</fpage>
<lpage>40191</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110.142356</pub-id>
<pub-id pub-id-type="pmid">20947502</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parada</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Egea</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Buendia</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Negredo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cunha</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>The microglial alpha7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2</article-title>
<source/>Antioxid Redox Signal
          <year>2013</year>
<volume>19</volume>
<fpage>1135</fpage>
<lpage>1148</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2012.4671</pub-id>
<pub-id pub-id-type="pmid">23311871</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velez-Fort</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Audinat</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Angulo</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Functional alpha 7-containing nicotinic receptors of NG2-expressing cells in the hippocampus</article-title>
<source/>Glia
          <year>2009</year>
<volume>57</volume>
<fpage>1104</fpage>
<lpage>1114</lpage>
<pub-id pub-id-type="doi">10.1002/glia.20834</pub-id>
<pub-id pub-id-type="pmid">19170184</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Steffensen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Functional alpha7beta2 nicotinic acetylcholine receptors expressed in hippocampal interneurons exhibit high sensitivity to pathological level of amyloid beta peptides</article-title>
<source/>BMC Neurosci
          <year>2012</year>
<volume>13</volume>
<fpage>155</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2202-13-155</pub-id>
<pub-id pub-id-type="pmid">23272676</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zoli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>George</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Lukas</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Pistillo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Maskos</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Whiteaker</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gotti</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The novel alpha7beta2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization</article-title>
<source/>Mol Pharmacol
          <year>2014</year>
<volume>86</volume>
<fpage>306</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1124/mol.114.093377</pub-id>
<pub-id pub-id-type="pmid">25002271</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frazier</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Strowbridge</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Papke</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Nicotinic receptors on local circuit neurons in dentate gyrus: a potential role in regulation of granule cell excitability</article-title>
<source/>J Neurophysiol
          <year>2003</year>
<volume>89</volume>
<fpage>3018</fpage>
<lpage>3028</lpage>
<pub-id pub-id-type="doi">10.1152/jn.01036.2002</pub-id>
<pub-id pub-id-type="pmid">12611982</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yakel</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Nicotinic ACh receptors in the hippocampus: role in excitability and plasticity</article-title>
<source/>Nicotine Tob Res
          <year>2012</year>
<volume>14</volume>
<fpage>1249</fpage>
<lpage>1257</lpage>
<pub-id pub-id-type="doi">10.1093/ntr/nts091</pub-id>
<pub-id pub-id-type="pmid">22472168</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamano</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Iwagaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yoshino</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nishibori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Stimulation of alpha7 nicotinic acetylcholine receptor inhibits CD14 and the toll-like receptor 4 expression in human monocytes</article-title>
<source/>Shock.
          <year>2006</year>
<volume>26</volume>
<fpage>358</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="doi">10.1097/01.shk.0000228168.86845.60</pub-id>
<pub-id pub-id-type="pmid">16980882</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshikawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kurokawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Atou</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kamochi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7</article-title>
<source/>Clin Exp Immunol
          <year>2006</year>
<volume>146</volume>
<fpage>116</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2249.2006.03169.x</pub-id>
<pub-id pub-id-type="pmid">16968406</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosas-Ballina</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Gallowitsch-Puerta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Valdes-Ferrer</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Chavan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Al-Abed</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tracey</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<article-title>The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE</article-title>
<source/>Mol Med
          <year>2009</year>
<volume>15</volume>
<fpage>195</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.2119/molmed.2009.00039</pub-id>
<pub-id pub-id-type="pmid">19593403</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nagayama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tadokoro</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Juji</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>TA</given-names>
</name>
</person-group>
<article-title>Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-alpha-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells</article-title>
<source/>J Immunol
          <year>1999</year>
<volume>162</volume>
<fpage>3865</fpage>
<lpage>3872</lpage>
<pub-id pub-id-type="pmid">10201904</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borovikova</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Ivanova</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Botchkina</surname>
<given-names>GI</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Abumrad</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Tracey</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<article-title>Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin</article-title>
<source/>Nature
          <year>2000</year>
<volume>405</volume>
<fpage>458</fpage>
<lpage>462</lpage>
<pub-id pub-id-type="doi">10.1038/35013070</pub-id>
<pub-id pub-id-type="pmid">10839541</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ochani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Amella</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Tanovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Susarla</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ulloa</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Al-Abed</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Czura</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Tracey</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<article-title>Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation</article-title>
<source/>Nature
          <year>2003</year>
<volume>421</volume>
<fpage>384</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="doi">10.1038/nature01339</pub-id>
<pub-id pub-id-type="pmid">12508119</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ochani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Justiniani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Al-Abed</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Metz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Tracey</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Ulloa</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis</article-title>
<source/>Nat Med
          <year>2004</year>
<volume>10</volume>
<fpage>1216</fpage>
<lpage>1221</lpage>
<pub-id pub-id-type="doi">10.1038/nm1124</pub-id>
<pub-id pub-id-type="pmid">15502843</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Lucas-Cerrillo</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Maldifassi</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Arnalich</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Renart</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Atienza</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Serantes</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cruces</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sanchez-Pacheco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Andres-Mateos</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Montiel</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Function of partially duplicated human alpha7 nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response</article-title>
<source/>J Biol Chem
          <year>2011</year>
<volume>286</volume>
<fpage>594</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110.180067</pub-id>
<pub-id pub-id-type="pmid">21047781</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Razani-Boroujerdi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Davila-Garcia</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Nandi</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Pena-Philippides</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Langley</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sopori</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>T cells express alpha7-nicotinic acetylcholine receptor subunits that require a functional TCR and leukocyte-specific protein tyrosine kinase for nicotine-induced Ca<sup>2+</sup> response</article-title>
<source/>J Immunol
          <year>2007</year>
<volume>179</volume>
<fpage>2889</fpage>
<lpage>2898</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.179.5.2889</pub-id>
<pub-id pub-id-type="pmid">17709503</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Rosa</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Dionisio</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Agriello</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bouzat</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Esandi Mdel</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Alpha 7 nicotinic acetylcholine receptor modulates lymphocyte activation</article-title>
<source/>Life Sci.
          <year>2009</year>
<volume>85</volume>
<fpage>444</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2009.07.010</pub-id>
<pub-id pub-id-type="pmid">19632243</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skok</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Kalashnik</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Koval</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Tsetlin</surname>
<given-names>VI</given-names>
</name>
<name>
<surname>Utkin</surname>
<given-names>YN</given-names>
</name>
<name>
<surname>Changeux</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Grailhe</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Functional nicotinic acetylcholine receptors are expressed in B lymphocyte-derived cell lines</article-title>
<source/>Mol Pharmacol
          <year>2003</year>
<volume>64</volume>
<fpage>885</fpage>
<lpage>889</lpage>
<pub-id pub-id-type="doi">10.1124/mol.64.4.885</pub-id>
<pub-id pub-id-type="pmid">14500745</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawashima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fujii</surname>
<given-names>YX</given-names>
</name>
<name>
<surname>Moriwaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Misawa</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Expression and function of genes encoding cholinergic components in murine immune cells</article-title>
<source/>Life Sci
          <year>2007</year>
<volume>80</volume>
<fpage>2314</fpage>
<lpage>2319</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2007.02.036</pub-id>
<pub-id pub-id-type="pmid">17383684</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saeed</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Varma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Peng-Nemeroff</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sherry</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Balakhaneh</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Huston</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tracey</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Al-Abed</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Metz</surname>
<given-names>CN</given-names>
</name>
</person-group>
<article-title>Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation</article-title>
<source/>J Exp Med
          <year>2005</year>
<volume>201</volume>
<fpage>1113</fpage>
<lpage>1123</lpage>
<pub-id pub-id-type="doi">10.1084/jem.20040463</pub-id>
<pub-id pub-id-type="pmid">15809354</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ndoye</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>TX</given-names>
</name>
<name>
<surname>Webber</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Grando</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Receptor-mediated inhibition of keratinocyte migration by nicotine involves modulations of calcium influx and intracellular concentration</article-title>
<source/>J Pharmacol Exp Ther
          <year>2000</year>
<volume>293</volume>
<fpage>973</fpage>
<lpage>981</lpage>
<pub-id pub-id-type="pmid">10869400</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chimienti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hogg</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Plantard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lehmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brakch</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hohl</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda</article-title>
<source/>Hum Mol Genet
          <year>2003</year>
<volume>12</volume>
<fpage>3017</fpage>
<lpage>3024</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddg320</pub-id>
<pub-id pub-id-type="pmid">14506129</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dowling</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rochelson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Way</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Al-Abed</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Metz</surname>
<given-names>CN</given-names>
</name>
</person-group>
<article-title>Nicotine inhibits cytokine production by placenta cells via NFkappaB: potential role in pregnancy-induced hypertension</article-title>
<source/>Mol Med
          <year>2007</year>
<volume>13</volume>
<fpage>576</fpage>
<lpage>583</lpage>
<pub-id pub-id-type="doi">10.2119/2007-00067.Dowling</pub-id>
<pub-id pub-id-type="pmid">17878927</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>XW</given-names>
</name>
<name>
<surname>Lindstrom</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Spindel</surname>
<given-names>ER</given-names>
</name>
</person-group>
<article-title>Nicotine activates and up-regulates nicotinic acetylcholine receptors in bronchial epithelial cells</article-title>
<source/>Am J Respir Cell Mol Biol
          <year>2009</year>
<volume>41</volume>
<fpage>93</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1165/rcmb.2008-0352OC</pub-id>
<pub-id pub-id-type="pmid">19097990</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schedel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schloss</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kluter</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bugert</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Human platelets express functional alpha7-nicotinic acetylcholine receptors</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>2011</year>
<volume>31</volume>
<fpage>928</fpage>
<lpage>934</lpage>
<pub-id pub-id-type="doi">10.1161/ATVBAHA.110.218297</pub-id>
<pub-id pub-id-type="pmid">21051662</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cancello</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zulian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maestrini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mencarelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Della Barba</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Invitti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liuzzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Di Blasio</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>The nicotinic acetylcholine receptor alpha7 in subcutaneous mature adipocytes: downregulation in human obesity and modulation by diet-induced weight loss</article-title>
<source/>Int J Obes (Lond)
          <year>2012</year>
<volume>36</volume>
<fpage>1552</fpage>
<lpage>1557</lpage>
<pub-id pub-id-type="doi">10.1038/ijo.2011.275</pub-id>
<pub-id pub-id-type="pmid">22270376</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waldburger</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Pavlov</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Tracey</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Firestein</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>Acetylcholine regulation of synoviocyte cytokine expression by the alpha7 nicotinic receptor</article-title>
<source/>Arthritis Rheum
          <year>2008</year>
<volume>58</volume>
<fpage>3439</fpage>
<lpage>3449</lpage>
<pub-id pub-id-type="doi">10.1002/art.23987</pub-id>
<pub-id pub-id-type="pmid">18975306</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>WX</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>Nicotinic acetylcholine receptor alpha7 subunit is time-dependently expressed in distinct cell types during skin wound healing in mice</article-title>
<source/>Histochem Cell Biol
          <year>2011</year>
<volume>135</volume>
<fpage>375</fpage>
<lpage>387</lpage>
<pub-id pub-id-type="doi">10.1007/s00418-011-0798-y</pub-id>
<pub-id pub-id-type="pmid">21437621</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Son</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Meizel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Acetylcholine causes an increase of intracellular calcium in human sperm</article-title>
<source/>Mol Hum Reprod
          <year>2005</year>
<volume>11</volume>
<fpage>881</fpage>
<lpage>889</lpage>
<pub-id pub-id-type="doi">10.1093/molehr/gah245</pub-id>
<pub-id pub-id-type="pmid">16421212</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Del Signore</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gotti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moretti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Paggi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Nicotinic acetylcholine receptor subtypes in the rat sympathetic ganglion: pharmacological characterization, subcellular distribution and effect of pre- and postganglionic nerve crush</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2004</year>
<volume>63</volume>
<fpage>138</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1093/jnen/63.2.138</pub-id>
<pub-id pub-id-type="pmid">14989600</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baxter</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Ramachandra</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mayne</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Elmslie</surname>
<given-names>KS</given-names>
</name>
</person-group>
<article-title>Functional expression of alpha7-nicotinic acetylcholine receptors by muscle afferent neurons</article-title>
<source/>J Neurophysiol
          <year>2014</year>
<volume>112</volume>
<fpage>1549</fpage>
<lpage>1558</lpage>
<pub-id pub-id-type="doi">10.1152/jn.00035.2014</pub-id>
<pub-id pub-id-type="pmid">24966300</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blumenthal</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Conroy</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kassner</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>DK</given-names>
</name>
</person-group>
<article-title>Detection of functional nicotinic receptors blocked by alpha-bungarotoxin on PC12 cells and dependence of their expression on post-translational events</article-title>
<source/>J Neurosci
          <year>1997</year>
<volume>17</volume>
<fpage>6094</fpage>
<lpage>6104</lpage>
<pub-id pub-id-type="pmid">9236221</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gerzanich</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Anand</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lindstrom</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Human alpha 7 acetylcholine receptor: cloning of the alpha 7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional alpha 7 homomers expressed in <italic>Xenopus</italic> oocytes</article-title>
<source/>Mol Pharmacol
          <year>1994</year>
<volume>45</volume>
<fpage>546</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="pmid">8145738</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Millar</surname>
<given-names>NS</given-names>
</name>
</person-group>
<article-title>Host cell-specific folding and assembly of the neuronal nicotinic acetylcholine receptor alpha7 subunit</article-title>
<source/>J Neurochem
          <year>1997</year>
<volume>68</volume>
<fpage>2140</fpage>
<lpage>2151</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1997.68052140.x</pub-id>
<pub-id pub-id-type="pmid">9109542</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parrish</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Rosas-Ballina</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gallowitsch-Puerta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ochani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ochani</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Hudson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Chavan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Czura</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Al-Abed</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tracey</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Pavlov</surname>
<given-names>VA</given-names>
</name>
</person-group>
<article-title>Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling</article-title>
<source/>Mol Med
          <year>2008</year>
<volume>14</volume>
<fpage>567</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="doi">10.2119/2008-00079.Parrish</pub-id>
<pub-id pub-id-type="pmid">18584048</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Polanowska-Grabowska</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dash</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Saucerman</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>MD</given-names>
</name>
</person-group>
<article-title>Identification and characterization of poly(I:C)-induced molecular responses attenuated by nicotine in mouse macrophages</article-title>
<source/>Mol Pharmacol
          <year>2013</year>
<volume>83</volume>
<fpage>61</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1124/mol.112.081497</pub-id>
<pub-id pub-id-type="pmid">23028093</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moriwaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shinagawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miyazawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Okuda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yabashi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Waguri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Misawa</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Primary sensory neuronal expression of SLURP-1, an endogenous nicotinic acetylcholine receptor ligand</article-title>
<source/>Neurosci Res
          <year>2009</year>
<volume>64</volume>
<fpage>403</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="doi">10.1016/j.neures.2009.04.014</pub-id>
<pub-id pub-id-type="pmid">19409425</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugano</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Murai</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Nicotine inhibits the production of inflammatory mediators in U937 cells through modulation of nuclear factor-kappaB activation</article-title>
<source/>Biochem Biophys Res Commun
          <year>1998</year>
<volume>252</volume>
<fpage>25</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.1998.9599</pub-id>
<pub-id pub-id-type="pmid">9813140</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Lucero</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Lukas</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Inducible, heterologous expression of human alpha7-nicotinic acetylcholine receptors in a native nicotinic receptor-null human clonal line</article-title>
<source/>Brain Res
          <year>1999</year>
<volume>825</volume>
<fpage>172</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(99)01066-5</pub-id>
<pub-id pub-id-type="pmid">10216184</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charpantier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wiesner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huh</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Ogier</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hoda</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Allaman</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Raggenbass</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Feuerbach</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fuhrer</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Alpha7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<fpage>9836</fpage>
<lpage>9849</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3497-05.2005</pub-id>
<pub-id pub-id-type="pmid">16251431</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feuerbach</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lingenhohl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dobbins</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mosbacher</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nozulak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hoyer</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Coupling of human nicotinic acetylcholine receptors alpha 7 to calcium channels in GH3 cells</article-title>
<source/>Neuropharmacology
          <year>2005</year>
<volume>48</volume>
<fpage>215</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.10.003</pub-id>
<pub-id pub-id-type="pmid">15695160</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villiger</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Szanto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Jaconi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blanchet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Buisson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Romand</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Expression of an alpha7 duplicate nicotinic acetylcholine receptor-related protein in human leukocytes</article-title>
<source/>J Neuroimmunol
          <year>2002</year>
<volume>126</volume>
<fpage>86</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-5728(02)00057-7</pub-id>
<pub-id pub-id-type="pmid">12020960</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>IW</given-names>
</name>
<name>
<surname>Wonnacott</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Why doesn’t nicotinic ACh receptor immunoreactivity knock out?</article-title>
<source/>Trends Neurosci
          <year>2005</year>
<volume>28</volume>
<fpage>343</fpage>
<lpage>345</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2005.04.010</pub-id>
<pub-id pub-id-type="pmid">15979499</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mogg</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Whiteaker</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McIntosh</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Wonnacott</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum</article-title>
<source/>J Pharmacol Exp Ther
          <year>2002</year>
<volume>302</volume>
<fpage>197</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.302.1.197</pub-id>
<pub-id pub-id-type="pmid">12065717</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gergalova</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lykhmus</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Komisarenko</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Skok</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>alpha7 nicotinic acetylcholine receptors control cytochrome c release from isolated mitochondria through kinase-mediated pathways</article-title>
<source/>Int J Biochem Cell Biol
          <year>2014</year>
<volume>49</volume>
<fpage>26</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2014.01.001</pub-id>
<pub-id pub-id-type="pmid">24412630</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lykhmus</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Gergalova</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Koval</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhmak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Komisarenko</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Skok</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction</article-title>
<source/>Int J Biochem Cell Biol
          <year>2014</year>
<volume>53</volume>
<fpage>246</fpage>
<lpage>252</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2014.05.030</pub-id>
<pub-id pub-id-type="pmid">24880090</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fucile</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Ca<sup>2+</sup> permeability of nicotinic acetylcholine receptors</article-title>
<source/>Cell Calcium
          <year>2004</year>
<volume>35</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.ceca.2003.08.006</pub-id>
<pub-id pub-id-type="pmid">14670366</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vijayaraghavan</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2001</year>
<volume>98</volume>
<fpage>4148</fpage>
<lpage>4153</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.071540198</pub-id>
<pub-id pub-id-type="pmid">11259680</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevens</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Fitzsimonds</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Picciotto</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation</article-title>
<source/>J Neurosci
          <year>2003</year>
<volume>23</volume>
<fpage>10093</fpage>
<lpage>10099</lpage>
<pub-id pub-id-type="pmid">14602824</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yakel</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Activation of alpha7 nicotinic acetylcholine receptors increases intracellular cAMP levels via activation of AC1 in hippocampal neurons</article-title>
<source/>Neuropharmacology
          <year>2015</year>
<volume>95</volume>
<fpage>405</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.04.016</pub-id>
<pub-id pub-id-type="pmid">25937212</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Medeiros</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Castello</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kitazawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baglietto-Vargas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Esbenshade</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Bitner</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Decker</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>LaFerla</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>alpha7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles</article-title>
<source/>Am J Pathol
          <year>2014</year>
<volume>184</volume>
<fpage>520</fpage>
<lpage>529</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2013.10.010</pub-id>
<pub-id pub-id-type="pmid">24269557</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kihara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shimohama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Honda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakamizo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shibasaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kume</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Akaike</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity</article-title>
<source/>J Biol Chem
          <year>2001</year>
<volume>276</volume>
<fpage>13541</fpage>
<lpage>13546</lpage>
<pub-id pub-id-type="pmid">11278378</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egea</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Buendia</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Leon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection</article-title>
<source/>Biochem Pharmacol
          <year>2015</year>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaw</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bencherif</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marrero</surname>
<given-names>MB</given-names>
</name>
</person-group>
<article-title>Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<fpage>44920</fpage>
<lpage>44924</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M204610200</pub-id>
<pub-id pub-id-type="pmid">12244045</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Jonge</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>van der Zanden</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>The</surname>
<given-names>FO</given-names>
</name>
<name>
<surname>Bijlsma</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>van Westerloo</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Bennink</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Berthoud</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Uematsu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S</given-names>
</name>
<name>
<surname>van den Wijngaard</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Boeckxstaens</surname>
<given-names>GE</given-names>
</name>
</person-group>
<article-title>Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway</article-title>
<source/>Nat Immunol
          <year>2005</year>
<volume>6</volume>
<fpage>844</fpage>
<lpage>851</lpage>
<pub-id pub-id-type="doi">10.1038/ni1229</pub-id>
<pub-id pub-id-type="pmid">16025117</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pena</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van der Zanden</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Deitch</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>de Jonge</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Ulloa</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Unphosphorylated STAT3 modulates alpha 7 nicotinic receptor signaling and cytokine production in sepsis</article-title>
<source/>Eur J Immunol
          <year>2010</year>
<volume>40</volume>
<fpage>2580</fpage>
<lpage>2589</lpage>
<pub-id pub-id-type="doi">10.1002/eji.201040540</pub-id>
<pub-id pub-id-type="pmid">20706987</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maldifassi</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Atienza</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Arnalich</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lopez-Collazo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cedillo</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Martin-Sanchez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bordas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Renart</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Montiel</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>A new IRAK-M-mediated mechanism implicated in the anti-inflammatory effect of nicotine via alpha7 nicotinic receptors in human macrophages</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e108397</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0108397</pub-id>
<pub-id pub-id-type="pmid">25259522</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tracey</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<article-title>Reflex control of immunity</article-title>
<source/>Nat Rev Immunol
          <year>2009</year>
<volume>9</volume>
<fpage>418</fpage>
<lpage>428</lpage>
<pub-id pub-id-type="doi">10.1038/nri2566</pub-id>
<pub-id pub-id-type="pmid">19461672</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tyagi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Agrawal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nath</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Inhibitory role of cholinergic system mediated via alpha7 nicotinic acetylcholine receptor in LPS-induced neuro-inflammation</article-title>
<source/>Innate Immun
          <year>2010</year>
<volume>16</volume>
<fpage>3</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1177/1753425909104680</pub-id>
<pub-id pub-id-type="pmid">19586999</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huston</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ochani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rosas-Ballina</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ochani</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pavlov</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Gallowitsch-Puerta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ashok</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Czura</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Foxwell</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tracey</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Ulloa</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis</article-title>
<source/>J Exp Med
          <year>2006</year>
<volume>203</volume>
<fpage>1623</fpage>
<lpage>1628</lpage>
<pub-id pub-id-type="doi">10.1084/jem.20052362</pub-id>
<pub-id pub-id-type="pmid">16785311</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kees</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Pongratz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kees</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Scholmerich</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Straub</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Via beta-adrenoceptors, stimulation of extrasplenic sympathetic nerve fibers inhibits lipopolysaccharide-induced TNF secretion in perfused rat spleen</article-title>
<source/>J Neuroimmunol
          <year>2003</year>
<volume>145</volume>
<fpage>77</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2003.09.011</pub-id>
<pub-id pub-id-type="pmid">14644033</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosas-Ballina</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Olofsson</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Ochani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Valdes-Ferrer</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Reardon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tusche</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Pavlov</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Chavan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Tracey</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<article-title>Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit</article-title>
<source/>Science
          <year>2011</year>
<volume>334</volume>
<fpage>98</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1126/science.1209985</pub-id>
<pub-id pub-id-type="pmid">21921156</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vida</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pena</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Deitch</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Ulloa</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>alpha7-cholinergic receptor mediates vagal induction of splenic norepinephrine</article-title>
<source/>J Immunol
          <year>2011</year>
<volume>186</volume>
<fpage>4340</fpage>
<lpage>4346</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1003722</pub-id>
<pub-id pub-id-type="pmid">21339364</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martelli</surname>
<given-names>D</given-names>
</name>
<name>
<surname>McKinley</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>McAllen</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>The cholinergic anti-inflammatory pathway: a critical review</article-title>
<source/>Auton Neurosci
          <year>2014</year>
<volume>182</volume>
<fpage>65</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1016/j.autneu.2013.12.007</pub-id>
<pub-id pub-id-type="pmid">24411268</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carrasco-Serrano</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Criado</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Glucocorticoid activation of the neuronal nicotinic acetylcholine receptor alpha7 subunit gene: involvement of transcription factor Egr-1</article-title>
<source/>FEBS Lett
          <year>2004</year>
<volume>566</volume>
<fpage>247</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2004.04.049</pub-id>
<pub-id pub-id-type="pmid">15147903</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandya</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Yakel</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies</article-title>
<source/>Biochem Pharmacol
          <year>2013</year>
<volume>86</volume>
<fpage>1054</fpage>
<lpage>1062</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2013.05.018</pub-id>
<pub-id pub-id-type="pmid">23732296</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bagdas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Targowska-Duda</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Arias</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Damaj</surname>
<given-names>MI</given-names>
</name>
</person-group>
<article-title>The antinociceptive and antiinflammatory properties of 3-furan-2-yl-<italic>N</italic>-<italic>p</italic>-tolyl-acrylamide, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors in mice</article-title>
<source/>Anesth Analg
          <year>2015</year>
<volume>121</volume>
<fpage>1369</fpage>
<lpage>1377</lpage>
<pub-id pub-id-type="doi">10.1213/ANE.0000000000000902</pub-id>
<pub-id pub-id-type="pmid">26280585</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalappa</surname>
<given-names>BI</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Uteshev</surname>
<given-names>VV</given-names>
</name>
</person-group>
<article-title>A positive allosteric modulator of alpha7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia</article-title>
<source/>Br J Pharmacol
          <year>2013</year>
<volume>169</volume>
<fpage>1862</fpage>
<lpage>1878</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12247</pub-id>
<pub-id pub-id-type="pmid">23713819</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Uteshev</surname>
<given-names>VV</given-names>
</name>
</person-group>
<article-title>A type-II positive allosteric modulator of alpha7 nAChRs reduces brain injury and improves neurological function after focal cerebral ischemia in rats</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e73581</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0073581</pub-id>
<pub-id pub-id-type="pmid">23951360</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gatson</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Simpkins</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Uteshev</surname>
<given-names>VV</given-names>
</name>
</person-group>
<article-title>High therapeutic potential of positive allosteric modulation of alpha7 nAChRs in a rat model of traumatic brain injury: proof-of-concept</article-title>
<source/>Brain Res Bull
          <year>2015</year>
<volume>112</volume>
<fpage>35</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainresbull.2015.01.008</pub-id>
<pub-id pub-id-type="pmid">25647232</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carnevale</surname>
<given-names>D</given-names>
</name>
<name>
<surname>De Simone</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Minghetti</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems</article-title>
<source/>CNS Neurol Disord: Drug Targets
          <year>2007</year>
<volume>6</volume>
<fpage>388</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="doi">10.2174/187152707783399193</pub-id>
<pub-id pub-id-type="pmid">18220778</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Nissen</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tsirka</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>The experimental autoimmune encephalomyelitis disease course is modulated by nicotine and other cigarette smoke components</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e107979</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0107979</pub-id>
<pub-id pub-id-type="pmid">25250777</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Leitzell</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Teo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Meleth</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Quick</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Lester</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Rapid upregulation of alpha7 nicotinic acetylcholine receptors by tyrosine dephosphorylation</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<fpage>3712</fpage>
<lpage>3723</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5389-03.2005</pub-id>
<pub-id pub-id-type="pmid">15814802</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Burli</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Huh</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Wiesner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Erb-Vogtli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gockeritz-Dujmovic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Moransard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nishimune</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Henley</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Fritschy</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Fuhrer</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>PICK1 interacts with alpha7 neuronal nicotinic acetylcholine receptors and controls their clustering</article-title>
<source/>Mol Cell Neurosci
          <year>2007</year>
<volume>35</volume>
<fpage>339</fpage>
<lpage>355</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2007.03.009</pub-id>
<pub-id pub-id-type="pmid">17467288</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Conroy</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Stawicki</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Nai</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Neff</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>DK</given-names>
</name>
</person-group>
<article-title>EphB receptors co-distribute with a nicotinic receptor subtype and regulate nicotinic downstream signaling in neurons</article-title>
<source/>Mol Cell Neurosci
          <year>2008</year>
<volume>38</volume>
<fpage>236</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2008.02.013</pub-id>
<pub-id pub-id-type="pmid">18403216</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castelan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Castillo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mulet</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sala</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sala</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dominguez Del Toro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Criado</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Molecular characterization and localization of the RIC-3 protein, an effector of nicotinic acetylcholine receptor expression</article-title>
<source/>J Neurochem
          <year>2008</year>
<volume>105</volume>
<fpage>617</fpage>
<lpage>627</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.05169.x</pub-id>
<pub-id pub-id-type="pmid">18179477</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grando</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Basic and clinical aspects of non-neuronal acetylcholine: biological and clinical significance of non-canonical ligands of epithelial nicotinic acetylcholine receptors</article-title>
<source/>J Pharmacol Sci
          <year>2008</year>
<volume>106</volume>
<fpage>174</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="doi">10.1254/jphs.FM0070087</pub-id>
<pub-id pub-id-type="pmid">18285656</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoppman-Chaney</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wain</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Seger</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Superneau</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Hodge</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Identification of single gene deletions at 15q13.3: further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype</article-title>
<source/>Clin Genet
          <year>2013</year>
<volume>83</volume>
<fpage>345</fpage>
<lpage>351</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2012.01925.x</pub-id>
<pub-id pub-id-type="pmid">22775350</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finlay-Schultz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Canastar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Short</surname>
<given-names>M</given-names>
</name>
<name>
<surname>El Gazzar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Coughlan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Transcriptional repression of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2alpha (AP-2alpha)</article-title>
<source/>J Biol Chem
          <year>2011</year>
<volume>286</volume>
<fpage>42123</fpage>
<lpage>42132</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.276014</pub-id>
<pub-id pub-id-type="pmid">21979958</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasui</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Scoles</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Horike</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meguro-Horike</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dunaway</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Lasalle</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain</article-title>
<source/>Hum Mol Genet
          <year>2011</year>
<volume>20</volume>
<fpage>4311</fpage>
<lpage>4323</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr357</pub-id>
<pub-id pub-id-type="pmid">21840925</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Jonge</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Ulloa</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation</article-title>
<source/>Br J Pharmacol
          <year>2007</year>
<volume>151</volume>
<fpage>915</fpage>
<lpage>929</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjp.0707264</pub-id>
<pub-id pub-id-type="pmid">17502850</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Estakhr</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kamran</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Renda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nashmi</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>cAMP-dependent protein kinase inhibits alpha7 nicotinic receptor activity in layer 1 cortical interneurons through activation of D1/D5 dopamine receptors</article-title>
<source/>J Physiol
          <year>2015</year>
<pub-id pub-id-type="pmid">25990637</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hilmas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Alkondon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rassoulpour</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schwarcz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Albuquerque</surname>
<given-names>EX</given-names>
</name>
</person-group>
<article-title>The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications</article-title>
<source/>J Neurosci
          <year>2001</year>
<volume>21</volume>
<fpage>7463</fpage>
<lpage>7473</lpage>
<pub-id pub-id-type="pmid">11567036</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dobelis</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Staley</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Lack of modulation of nicotinic acetylcholine alpha-7 receptor currents by kynurenic acid in adult hippocampal interneurons</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e41108</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0041108</pub-id>
<pub-id pub-id-type="pmid">22848433</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Indersmitten</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lester</surname>
<given-names>HA</given-names>
</name>
</person-group>
<article-title>The duplicated alpha7 subunits assemble and form functional nicotinic receptors with the full-length alpha7</article-title>
<source/>J Biol Chem
          <year>2014</year>
<volume>289</volume>
<fpage>26451</fpage>
<lpage>26463</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M114.582858</pub-id>
<pub-id pub-id-type="pmid">25056953</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costantini</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Coimbra</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Eliceiri</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Baird</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>CHRFAM7A, a human-specific and partially duplicated alpha7-nicotinic acetylcholine receptor gene with the potential to specify a human-specific inflammatory response to injury</article-title>
<source/>J Leukoc Biol
          <year>2015</year>
<volume>97</volume>
<fpage>247</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1189/jlb.4RU0814-381R</pub-id>
<pub-id pub-id-type="pmid">25473097</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benfante</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Antonini</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>De Pizzol</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gotti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Clementi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Locati</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fornasari</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Expression of the alpha7 nAChR subunit duplicate form (CHRFAM7A) is down-regulated in the monocytic cell line THP-1 on treatment with LPS</article-title>
<source/>J Neuroimmunol
          <year>2011</year>
<volume>230</volume>
<fpage>74</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2010.09.008</pub-id>
<pub-id pub-id-type="pmid">20926142</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woolf</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Butcher</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>Cholinergic systems mediate action from movement to higher consciousness</article-title>
<source/>Behav Brain Res
          <year>2011</year>
<volume>221</volume>
<fpage>488</fpage>
<lpage>498</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2009.12.046</pub-id>
<pub-id pub-id-type="pmid">20060422</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowe</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Mercer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Casetti</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sendt</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Giaroli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Shergill</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Tracy</surname>
<given-names>DK</given-names>
</name>
</person-group>
<article-title>Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia</article-title>
<source/>J Psychopharmacol
          <year>2015</year>
<volume>29</volume>
<fpage>197</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1177/0269881114564096</pub-id>
<pub-id pub-id-type="pmid">25567553</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Briggs</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists</article-title>
<source/>Neuropharmacology
          <year>1998</year>
<volume>37</volume>
<fpage>1095</fpage>
<lpage>1102</lpage>
<pub-id pub-id-type="doi">10.1016/S0028-3908(98)00110-5</pub-id>
<pub-id pub-id-type="pmid">9833639</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wessler</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans</article-title>
<source/>Br J Pharmacol
          <year>2008</year>
<volume>154</volume>
<fpage>1558</fpage>
<lpage>1571</lpage>
<pub-id pub-id-type="doi">10.1038/bjp.2008.185</pub-id>
<pub-id pub-id-type="pmid">18500366</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quick</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Lester</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Desensitization of neuronal nicotinic receptors</article-title>
<source/>J Neurobiol
          <year>2002</year>
<volume>53</volume>
<fpage>457</fpage>
<lpage>478</lpage>
<pub-id pub-id-type="doi">10.1002/neu.10109</pub-id>
<pub-id pub-id-type="pmid">12436413</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papke</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Kem</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Soti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lopez-Hernandez</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Horenstein</surname>
<given-names>NA</given-names>
</name>
</person-group>
<article-title>Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotine</article-title>
<source/>J Pharmacol Exp Ther
          <year>2009</year>
<volume>329</volume>
<fpage>791</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.108.150151</pub-id>
<pub-id pub-id-type="pmid">19223664</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frazier</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Rollins</surname>
<given-names>YD</given-names>
</name>
<name>
<surname>Breese</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dunwiddie</surname>
<given-names>TV</given-names>
</name>
</person-group>
<article-title>Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells</article-title>
<source/>J Neurosci
          <year>1998</year>
<volume>18</volume>
<fpage>1187</fpage>
<lpage>1195</lpage>
<pub-id pub-id-type="pmid">9454829</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wessler</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Reinheimer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Klapproth</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Racke</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hammer</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Mammalian glial cells in culture synthesize acetylcholine</article-title>
<source/>Naunyn Schmiedebergs Arch Pharmacol
          <year>1997</year>
<volume>356</volume>
<fpage>694</fpage>
<lpage>697</lpage>
<pub-id pub-id-type="doi">10.1007/PL00005107</pub-id>
<pub-id pub-id-type="pmid">9402051</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alkondon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Cortes</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Maelicke</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Albuquerque</surname>
<given-names>EX</given-names>
</name>
</person-group>
<article-title>Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons</article-title>
<source/>Eur J Neurosci
          <year>1997</year>
<volume>9</volume>
<fpage>2734</fpage>
<lpage>2742</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.1997.tb01702.x</pub-id>
<pub-id pub-id-type="pmid">9517478</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bencherif</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Narla</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Stachowiak</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Alpha7 neuronal nicotinic receptor: a pluripotent target for diseases of the central nervous system</article-title>
<source/>CNS Neurol Disord Drug Targets
          <year>2014</year>
<volume>13</volume>
<fpage>836</fpage>
<lpage>845</lpage>
<pub-id pub-id-type="doi">10.2174/1871527313666140711094525</pub-id>
<pub-id pub-id-type="pmid">25012615</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danese</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moffitt</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Pariante</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Ambler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Poulton</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Caspi</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Elevated inflammation levels in depressed adults with a history of childhood maltreatment</article-title>
<source/>Arch Gen Psychiatry
          <year>2008</year>
<volume>65</volume>
<fpage>409</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.65.4.409</pub-id>
<pub-id pub-id-type="pmid">18391129</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kendler</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Hettema</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Butera</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Prescott</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Life event dimensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety</article-title>
<source/>Arch Gen Psychiatry
          <year>2003</year>
<volume>60</volume>
<fpage>789</fpage>
<lpage>796</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.60.8.789</pub-id>
<pub-id pub-id-type="pmid">12912762</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Janicki-Deverts</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Doyle</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rabin</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>RB</given-names>
</name>
</person-group>
<article-title>Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2012</year>
<volume>109</volume>
<fpage>5995</fpage>
<lpage>5999</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1118355109</pub-id>
<pub-id pub-id-type="pmid">22474371</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Copeland</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Wolke</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lereya</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Shanahan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Worthman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Costello</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>Childhood bullying involvement predicts low-grade systemic inflammation into adulthood</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2014</year>
<volume>111</volume>
<fpage>7570</fpage>
<lpage>7575</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1323641111</pub-id>
<pub-id pub-id-type="pmid">24821813</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slavich</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>SW</given-names>
</name>
</person-group>
<article-title>The emerging field of human social genomics</article-title>
<source/>Clin Psychol Sci
          <year>2013</year>
<volume>1</volume>
<fpage>331</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="doi">10.1177/2167702613478594</pub-id>
<pub-id pub-id-type="pmid">23853742</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pace</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Mletzko</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Alagbe</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Musselman</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Nemeroff</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Heim</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress</article-title>
<source/>Am J Psychiatry
          <year>2006</year>
<volume>163</volume>
<fpage>1630</fpage>
<lpage>1633</lpage>
<pub-id pub-id-type="doi">10.1176/ajp.2006.163.9.1630</pub-id>
<pub-id pub-id-type="pmid">16946190</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fok</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nicholls</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kobor</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Low early-life social class leaves a biological residue manifested by decreased glucocorticoid and increased proinflammatory signaling</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2009</year>
<volume>106</volume>
<fpage>14716</fpage>
<lpage>14721</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0902971106</pub-id>
<pub-id pub-id-type="pmid">19617551</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weinstein</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Deuster</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Bonsall</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Tracy</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Kop</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Neurohormonal and inflammatory hyper-responsiveness to acute mental stress in depression</article-title>
<source/>Biol Psychol
          <year>2010</year>
<volume>84</volume>
<fpage>228</fpage>
<lpage>234</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsycho.2010.01.016</pub-id>
<pub-id pub-id-type="pmid">20117167</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>FC</given-names>
</name>
</person-group>
<article-title>Antimicrobial reactive oxygen and nitrogen species: concepts and controversies</article-title>
<source/>Nat Rev Microbiol
          <year>2004</year>
<volume>2</volume>
<fpage>820</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="doi">10.1038/nrmicro1004</pub-id>
<pub-id pub-id-type="pmid">15378046</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sorci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Faivre</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Inflammation and oxidative stress in vertebrate host-parasite systems</article-title>
<source/>Philos Trans R Soc Lond B Biol Sci
          <year>2009</year>
<volume>364</volume>
<fpage>71</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1098/rstb.2008.0151</pub-id>
<pub-id pub-id-type="pmid">18930878</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neurauter</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schrocksnadel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Scholl-Burgi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sperner-Unterweger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schubert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ledochowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Chronic immune stimulation correlates with reduced phenylalanine turnover</article-title>
<source/>Curr Drug Metab
          <year>2008</year>
<volume>9</volume>
<fpage>622</fpage>
<lpage>627</lpage>
<pub-id pub-id-type="doi">10.2174/138920008785821738</pub-id>
<pub-id pub-id-type="pmid">18781914</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>McGregor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bordia</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Alpha7 nicotinic receptors as therapeutic targets for Parkinson’s disease</article-title>
<source/>Biochem Pharmacol.
          <year>2015</year>
<pub-id pub-id-type="pmid">26093062</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bitner</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Nikkel</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Markosyan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Otte</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Puttfarcken</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gopalakrishnan</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo</article-title>
<source/>Brain Res
          <year>2009</year>
<volume>1265</volume>
<fpage>65</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2009.01.069</pub-id>
<pub-id pub-id-type="pmid">19230830</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Oscos</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pena</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Housini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cuevas-Olguin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Saderi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Salgado Delgado</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Galindo Charles</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Salgado Burgos</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rose-John</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Flores</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kilgard</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Atzori</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Activation of the anti-inflammatory reflex blocks lipopolysaccharide-induced decrease in synaptic inhibition in the temporal cortex of the rat</article-title>
<source/>J Neurosci Res.
          <year>2015</year>
<volume>93</volume>
<fpage>859</fpage>
<lpage>865</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.23550</pub-id>
<pub-id pub-id-type="pmid">25626997</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howland</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Vagus nerve stimulation</article-title>
<source/>Curr Behav Neurosci Rep
          <year>2014</year>
<volume>1</volume>
<fpage>64</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1007/s40473-014-0010-5</pub-id>
<pub-id pub-id-type="pmid">24834378</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marangell</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Rush</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>George</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Sackeim</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Husain</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Nahas</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lisanby</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes</article-title>
<source/>Biol Psychiatry
          <year>2002</year>
<volume>51</volume>
<fpage>280</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(01)01343-9</pub-id>
<pub-id pub-id-type="pmid">11958778</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rush</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Sackeim</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Marangell</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>George</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Brannan</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lavori</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Howland</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kling</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rittberg</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ninan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Conway</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Barry</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study</article-title>
<source/>Biol Psychiatry
          <year>2005</year>
<volume>58</volume>
<fpage>355</fpage>
<lpage>363</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2005.05.024</pub-id>
<pub-id pub-id-type="pmid">16139581</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bajbouj</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Merkl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schlaepfer</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Frick</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zobel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>W</given-names>
</name>
<name>
<surname>O’Keane</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Corcoran</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Adolfsson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Trimble</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rau</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hoff</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Padberg</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Muller-Siecheneder</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Audenaert</surname>
<given-names>K</given-names>
</name>
<name>
<surname>van den Abbeele</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Christmas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Eljamel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Heuser</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Two-year outcome of vagus nerve stimulation in treatment-resistant depression</article-title>
<source/>J Clin Psychopharmacol
          <year>2010</year>
<volume>30</volume>
<fpage>273</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e3181db8831</pub-id>
<pub-id pub-id-type="pmid">20473062</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slattery</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>ID</given-names>
</name>
</person-group>
<article-title>Chronic icv oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats</article-title>
<source/>Neuropharmacology
          <year>2010</year>
<volume>58</volume>
<fpage>56</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2009.06.038</pub-id>
<pub-id pub-id-type="pmid">19589349</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCann</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Oxytocin excites gastric-related neurones in rat dorsal vagal complex</article-title>
<source/>J Physiol
          <year>1990</year>
<volume>428</volume>
<fpage>95</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1113/jphysiol.1990.sp018202</pub-id>
<pub-id pub-id-type="pmid">2231433</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clodi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vila</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Geyeregger</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Riedl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stulnig</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Struck</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Luger</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Luger</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men</article-title>
<source/>Am J Physiol Endocrinol Metab.
          <year>2008</year>
<volume>295</volume>
<fpage>E686</fpage>
<lpage>E691</lpage>
<pub-id pub-id-type="doi">10.1152/ajpendo.90263.2008</pub-id>
<pub-id pub-id-type="pmid">18593851</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Najjar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pearlman</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Neuroinflammation and white matter pathology in schizophrenia: systematic review</article-title>
<source/>Schizophr Res
          <year>2015</year>
<volume>161</volume>
<fpage>102</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2014.04.041</pub-id>
<pub-id pub-id-type="pmid">24948485</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Developmental neuroinflammation and schizophrenia</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>2013</year>
<volume>42</volume>
<fpage>20</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2011.11.003</pub-id>
<pub-id pub-id-type="pmid">22122877</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aberg</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bukszar</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McClay</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Khachane</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Andreassen</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Blackwood</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Corvin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Djurovic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gurling</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ophoff</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pato</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Pato</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Riley</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kendler</surname>
<given-names>K</given-names>
</name>
<name>
<surname>O’Donovan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Craddock</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kirov</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rujescu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>St Clair</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Werge</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hultman</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Delisi</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>van den Oord</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>A comprehensive family-based replication study of schizophrenia genes</article-title>
<source/>JAMA Psychiatry
          <year>2013</year>
<volume>70</volume>
<fpage>573</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.288</pub-id>
<pub-id pub-id-type="pmid">23894747</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marco</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Antonio</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Antonina</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Alessandro</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Concetta</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Genes involved in pruning and inflammation are enriched in a large mega-sample of patients affected by schizophrenia and bipolar disorder and controls</article-title>
<source/>Psychiatry Res
          <year>2015</year>
<volume>228</volume>
<fpage>945</fpage>
<lpage>949</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2015.06.013</pub-id>
<pub-id pub-id-type="pmid">26160200</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Berckel</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Bossong</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Boellaard</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kloet</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schuitemaker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Caspers</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Luurtsema</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Windhorst</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Cahn</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lammertsma</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study</article-title>
<source/>Biol Psychiatry
          <year>2008</year>
<volume>64</volume>
<fpage>820</fpage>
<lpage>822</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2008.04.025</pub-id>
<pub-id pub-id-type="pmid">18534557</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doorduin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>de Groot</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Dierckx</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>HC</given-names>
</name>
</person-group>
<article-title>Neuroinflammation in schizophrenia-related psychosis: a PET study</article-title>
<source/>J Nucl Med
          <year>2009</year>
<volume>50</volume>
<fpage>1801</fpage>
<lpage>1807</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.109.066647</pub-id>
<pub-id pub-id-type="pmid">19837763</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monji</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kanba</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Cytokines and schizophrenia: microglia hypothesis of schizophrenia</article-title>
<source/>Psychiatry Clin Neurosci
          <year>2009</year>
<volume>63</volume>
<fpage>257</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="doi">10.1111/j.1440-1819.2009.01945.x</pub-id>
<pub-id pub-id-type="pmid">19579286</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Seabolt</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Mellor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects</article-title>
<source/>Biol Psychiatry
          <year>2011</year>
<volume>70</volume>
<fpage>663</fpage>
<lpage>671</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2011.04.013</pub-id>
<pub-id pub-id-type="pmid">21641581</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasayama</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Teraishi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hori</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ota</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Arima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Higuchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Amano</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kunugi</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder</article-title>
<source/>J Psychiatr Res
          <year>2013</year>
<volume>47</volume>
<fpage>401</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2012.12.001</pub-id>
<pub-id pub-id-type="pmid">23290488</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>di Penta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Reix</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fernandez-Diez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Villanueva</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Errea</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Escala</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vandenbroeck</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Comella</surname>
<given-names>JX</given-names>
</name>
<name>
<surname>Villoslada</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e54722</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0054722</pub-id>
<pub-id pub-id-type="pmid">23431360</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantyla</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mantere</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Raij</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Kieseppa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Laitinen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Leiviska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Torniainen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tuominen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vaarala</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Suvisaari</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Altered activation of innate immunity associates with white matter volume and diffusion in first-episode psychosis</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0125112</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0125112</pub-id>
<pub-id pub-id-type="pmid">25970596</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chapman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ragg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McGeechan</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Citation bias in reported smoking prevalence in people with schizophrenia</article-title>
<source/>Aust N Z J Psychiatry
          <year>2009</year>
<volume>43</volume>
<fpage>277</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1080/00048670802653372</pub-id>
<pub-id pub-id-type="pmid">19221917</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia</article-title>
<source/>Biol Psychiatry
          <year>1995</year>
<volume>38</volume>
<fpage>22</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1016/0006-3223(94)00252-X</pub-id>
<pub-id pub-id-type="pmid">7548469</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Court</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Spurden</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lloyd</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McKeith</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kerwin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus</article-title>
<source/>J Neurochem
          <year>1999</year>
<volume>73</volume>
<fpage>1590</fpage>
<lpage>1597</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0731590.x</pub-id>
<pub-id pub-id-type="pmid">10501205</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname>
<given-names>ZZ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Blennow</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nordberg</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain</article-title>
<source/>NeuroReport
          <year>1999</year>
<volume>10</volume>
<fpage>1779</fpage>
<lpage>1782</lpage>
<pub-id pub-id-type="doi">10.1097/00001756-199906030-00028</pub-id>
<pub-id pub-id-type="pmid">10501574</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Genetics of chromosome 15q13-q14 in schizophrenia</article-title>
<source/>Biol Psychiatry
          <year>2006</year>
<volume>60</volume>
<fpage>115</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2006.03.054</pub-id>
<pub-id pub-id-type="pmid">16843094</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masurel-Paulet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Andrieux</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Callier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cuisset</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>Caignec C</given-names>
</name>
<name>
<surname>Holder</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thauvin-Robinet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Doray</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Flori</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Alex-Cordier</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Beri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boute</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Delobel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dieux</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vallee</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jaillard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Odent</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Isidor</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Beneteau</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vigneron</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bilan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gilbert-Dussardier</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dubourg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Labalme</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bidon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gautier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pernes</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pinoit</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Huet</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mugneret</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Aral</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jonveaux</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sanlaville</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Faivre</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Delineation of 15q13.3 microdeletions</article-title>
<source/>Clin Genet
          <year>2010</year>
<volume>78</volume>
<fpage>149</fpage>
<lpage>161</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2010.01374.x</pub-id>
<pub-id pub-id-type="pmid">20236110</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gillentine</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Schaaf</surname>
<given-names>CP</given-names>
</name>
</person-group>
<article-title>The human clinical phenotypes of altered CHRNA7 copy number</article-title>
<source/>Biochem Pharmacol
          <year>2015</year>
<pub-id pub-id-type="pmid">26095975</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rakhilin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Drisdel</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Sagher</surname>
<given-names>D</given-names>
</name>
<name>
<surname>McGehee</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Vallejo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>WN</given-names>
</name>
</person-group>
<article-title>alpha-bungarotoxin receptors contain alpha7 subunits in two different disulfide-bonded conformations</article-title>
<source/>J Cell Biol
          <year>1999</year>
<volume>146</volume>
<fpage>203</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="pmid">10402471</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gault</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Logel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vianzon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Short</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Drebing</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Venn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sirota</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zerbe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Olincy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia</article-title>
<source/>Arch Gen Psychiatry
          <year>2002</year>
<volume>59</volume>
<fpage>1085</fpage>
<lpage>1096</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.59.12.1085</pub-id>
<pub-id pub-id-type="pmid">12470124</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinkus</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Gault</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Logel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Short</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Christian</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Lyon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A 2-base pair deletion polymorphism in the partial duplication of the alpha7 nicotinic acetylcholine gene (CHRFAM7A) on chromosome 15q14 is associated with schizophrenia</article-title>
<source/>Brain Res
          <year>2009</year>
<volume>1291</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2009.07.041</pub-id>
<pub-id pub-id-type="pmid">19631623</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Targeting of alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia and the use of auditory sensory gating as a translational biomarker</article-title>
<source/>Curr Pharm Des
          <year>2015</year>
<volume>21</volume>
<fpage>3797</fpage>
<lpage>3806</lpage>
<pub-id pub-id-type="doi">10.2174/1381612821666150605111345</pub-id>
<pub-id pub-id-type="pmid">26044974</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beinat</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Banister</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Herrera</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kassiou</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The therapeutic potential of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia</article-title>
<source/>CNS Drugs
          <year>2015</year>
<volume>29</volume>
<fpage>529</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="doi">10.1007/s40263-015-0260-0</pub-id>
<pub-id pub-id-type="pmid">26242477</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keefe</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Dgetluck</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gawryl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Moebius</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Lombardo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hilt</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia</article-title>
<source/>Neuropsychopharmacology
          <year>2015</year>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noroozian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ghasemi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hosseini</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Modabbernia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Khodaie-Ardakani</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Mirshafiee</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Farokhnia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tajdini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rezaei</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Salehi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ashrafi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yekehtaz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tabrizi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Akhondzadeh</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia</article-title>
<source/>Psychopharmacology
          <year>2013</year>
<volume>228</volume>
<fpage>595</fpage>
<lpage>602</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-013-3064-2</pub-id>
<pub-id pub-id-type="pmid">23515583</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umbricht</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Keefe</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Garibaldi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Santarelli</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>A randomized, placebo-controlled study investigating the nicotinic alpha7 agonist, RG3487, for cognitive deficits in schizophrenia</article-title>
<source/>Neuropsychopharmacology
          <year>2014</year>
<volume>39</volume>
<fpage>1568</fpage>
<lpage>1577</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2014.17</pub-id>
<pub-id pub-id-type="pmid">24549101</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>AQ</given-names>
</name>
</person-group>
<article-title>Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study</article-title>
<source/>Schizophr Res
          <year>2006</year>
<volume>88</volume>
<fpage>102</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2006.07.010</pub-id>
<pub-id pub-id-type="pmid">16959472</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lieberman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Dunbar</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Segreti</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Girgis</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Seoane</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Beaver</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hosford</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia</article-title>
<source/>Neuropsychopharmacology
          <year>2013</year>
<volume>38</volume>
<fpage>968</fpage>
<lpage>975</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2012.259</pub-id>
<pub-id pub-id-type="pmid">23303043</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Olincy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Allensworth</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Guzman-Bonilla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Clement</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Kutnick</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pender</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Zerbe</surname>
<given-names>GO</given-names>
</name>
<name>
<surname>Soti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kem</surname>
<given-names>WR</given-names>
</name>
</person-group>
<article-title>Initial phase 2 trial of a nicotinic agonist in schizophrenia</article-title>
<source/>Am J Psychiatry
          <year>2008</year>
<volume>165</volume>
<fpage>1040</fpage>
<lpage>1047</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2008.07071135</pub-id>
<pub-id pub-id-type="pmid">18381905</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michelmore</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Croskery</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nozulak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hoyer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Longato</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bouhelal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Feuerbach</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Study of the calcium dynamics of the human alpha4beta2, alpha3beta4 and alpha1beta1gammadelta nicotinic acetylcholine receptors</article-title>
<source/>Naunyn Schmiedebergs Arch Pharmacol
          <year>2002</year>
<volume>366</volume>
<fpage>235</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1007/s00210-002-0589-z</pub-id>
<pub-id pub-id-type="pmid">12172706</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boggs</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cortes-Briones</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>D’Souza</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia</article-title>
<source/>Curr Pharm Des
          <year>2014</year>
<volume>20</volume>
<fpage>5077</fpage>
<lpage>5092</lpage>
<pub-id pub-id-type="doi">10.2174/1381612819666131216121019</pub-id>
<pub-id pub-id-type="pmid">24345265</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ancin</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Barabash</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vazquez-Alvarez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Sanchez-Morla</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Aparicio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pelaez</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Evidence for association of the non-duplicated region of CHRNA7 gene with bipolar disorder but not with Schizophrenia</article-title>
<source/>Psychiatr Genet
          <year>2010</year>
<volume>20</volume>
<fpage>289</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1097/YPG.0b013e32833a9b7a</pub-id>
<pub-id pub-id-type="pmid">20463630</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lisi</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Lotronex withdrawal</article-title>
<source/>Arch Intern Med
          <year>2002</year>
<volume>162</volume>
<fpage>101</fpage>
<pub-id pub-id-type="doi">10.1001/archinte.162.1.101</pub-id>
<pub-id pub-id-type="pmid">11784233</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spiller</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome</article-title>
<source/>Curr Opin Pharmacol
          <year>2011</year>
<volume>11</volume>
<fpage>68</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2011.02.005</pub-id>
<pub-id pub-id-type="pmid">21398180</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Profile of minocycline and its potential in the treatment of schizophrenia</article-title>
<source/>Neuropsychiatr Dis Treat
          <year>2014</year>
<volume>10</volume>
<fpage>1103</fpage>
<lpage>1111</lpage>
<pub-id pub-id-type="doi">10.2147/NDT.S64236</pub-id>
<pub-id pub-id-type="pmid">24971013</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benazzi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Bipolar disorder–focus on bipolar II disorder and mixed depression</article-title>
<source/>Lancet
          <year>2007</year>
<volume>369</volume>
<fpage>935</fpage>
<lpage>945</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60453-X</pub-id>
<pub-id pub-id-type="pmid">17368155</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leboyer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Soreca</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tamouza</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kupfer</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Can bipolar disorder be viewed as a multi-system inflammatory disease?</article-title>
<source/>J Affect Disord
          <year>2012</year>
<volume>141</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2011.12.049</pub-id>
<pub-id pub-id-type="pmid">22497876</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maletic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Raison</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Integrated neurobiology of bipolar disorder</article-title>
<source/>Front Psychiatry
          <year>2014</year>
<volume>5</volume>
<fpage>98</fpage>
<pub-id pub-id-type="doi">10.3389/fpsyt.2014.00098</pub-id>
<pub-id pub-id-type="pmid">25202283</pub-id>
</element-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Andreazza</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>The potential role of the NLRP3 inflammasome as a link between mitochondrial complex I dysfunction and inflammation in bipolar disorder</article-title>
<source/>Neural Plast
          <year>2015</year>
<volume>2015</volume>
<fpage>408136</fpage>
<pub-id pub-id-type="pmid">26075098</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Etain</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bellivier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mathieu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Leboyer</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Beyond genetics: childhood affective trauma in bipolar disorder</article-title>
<source/>Bipolar Disord
          <year>2008</year>
<volume>10</volume>
<fpage>867</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-5618.2008.00635.x</pub-id>
<pub-id pub-id-type="pmid">19594502</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickerson</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Stallings</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Origoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boronow</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yolken</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>2007</year>
<volume>31</volume>
<fpage>952</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2007.02.018</pub-id>
<pub-id pub-id-type="pmid">17391822</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname>
<given-names>BI</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Soczynska</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature</article-title>
<source/>J Clin Psychiatry
          <year>2009</year>
<volume>70</volume>
<fpage>1078</fpage>
<lpage>1090</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.08r04505</pub-id>
<pub-id pub-id-type="pmid">19497250</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munkholm</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brauner</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Vinberg</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis</article-title>
<source/>J Psychiatr Res
          <year>2013</year>
<volume>47</volume>
<fpage>1119</fpage>
<lpage>1133</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2013.05.018</pub-id>
<pub-id pub-id-type="pmid">23768870</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modabbernia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Taslimi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brietzke</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ashrafi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies</article-title>
<source/>Biol Psychiatry
          <year>2013</year>
<volume>74</volume>
<fpage>15</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2013.01.007</pub-id>
<pub-id pub-id-type="pmid">23419545</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smoller</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Disorders and borders: psychiatric genetics and nosology</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2013</year>
<volume>162B</volume>
<fpage>559</fpage>
<lpage>578</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32174</pub-id>
<pub-id pub-id-type="pmid">24132891</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Harry</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HW</given-names>
</name>
</person-group>
<article-title>Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients</article-title>
<source/>Mol Psychiatry
          <year>2010</year>
<volume>15</volume>
<fpage>384</fpage>
<lpage>392</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2009.47</pub-id>
<pub-id pub-id-type="pmid">19488045</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jakobsson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bjerke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sahebi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Isgren</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ekman</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Sellgren</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zetterberg</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Blennow</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Palsson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Landen</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Monocyte and microglial activation in patients with mood-stabilized bipolar disorder</article-title>
<source/>J Psychiatry Neurosci
          <year>2015</year>
<volume>40</volume>
<fpage>250</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="doi">10.1503/jpn.140183</pub-id>
<pub-id pub-id-type="pmid">25768030</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haarman</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Riemersma-van der Lek</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>de Groot</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Ruhe</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Zandstra</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schoevers</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Drexhage</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Nolen</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Doorduin</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Neuroinflammation in bipolar disorder—a [(11)C]-(R)-PK11195 positron emission tomography study</article-title>
<source/>Brain Behav Immun.
          <year>2014</year>
<volume>40</volume>
<fpage>219</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2014.03.016</pub-id>
<pub-id pub-id-type="pmid">24703991</pub-id>
</element-citation>
</ref>
<ref id="CR178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Association study of the human partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant with bipolar disorder</article-title>
<source/>Neurosci Lett
          <year>2004</year>
<volume>355</volume>
<fpage>69</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2003.10.043</pub-id>
<pub-id pub-id-type="pmid">14729237</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Besson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>David</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Baudonnat</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cazala</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Guilloux</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Reperant</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cloez-Tayarani</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Changeux</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Gardier</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Granon</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice</article-title>
<source/>Psychopharmacology
          <year>2012</year>
<volume>220</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-011-2422-1</pub-id>
<pub-id pub-id-type="pmid">21901321</pub-id>
</element-citation>
</ref>
<ref id="CR180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beaulieu</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sotnikova</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Marion</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lefkowitz</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Gainetdinov</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Caron</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior</article-title>
<source/>Cell
          <year>2005</year>
<volume>122</volume>
<fpage>261</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2005.05.012</pub-id>
<pub-id pub-id-type="pmid">16051150</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>GSK-3beta activity and hyperdopamine-dependent behaviors</article-title>
<source/>Neurosci Biobehav Rev
          <year>2011</year>
<volume>35</volume>
<fpage>645</fpage>
<lpage>654</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2010.08.001</pub-id>
<pub-id pub-id-type="pmid">20727368</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>LQ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JZ</given-names>
</name>
</person-group>
<article-title>Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments</article-title>
<source/>J Neurosci
          <year>2007</year>
<volume>27</volume>
<fpage>12211</fpage>
<lpage>12220</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3321-07.2007</pub-id>
<pub-id pub-id-type="pmid">17989287</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peineau</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Taghibiglou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Saule</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bouschet</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Isaac</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Bortolotto</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Collingridge</surname>
<given-names>GL</given-names>
</name>
</person-group>
<article-title>LTP inhibits LTD in the hippocampus via regulation of GSK3beta</article-title>
<source/>Neuron
          <year>2007</year>
<volume>53</volume>
<fpage>703</fpage>
<lpage>717</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2007.01.029</pub-id>
<pub-id pub-id-type="pmid">17329210</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peineau</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Taghibiglou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bortolotto</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Collingridge</surname>
<given-names>GL</given-names>
</name>
</person-group>
<article-title>The role of GSK-3 in synaptic plasticity</article-title>
<source/>Br J Pharmacol
          <year>2008</year>
<volume>153</volume>
<issue>Suppl 1</issue>
<fpage>S428</fpage>
<lpage>S437</lpage>
<pub-id pub-id-type="pmid">18311157</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frank</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Fossella</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Neurogenetics and pharmacology of learning, motivation, and cognition</article-title>
<source/>Neuropsychopharmacology
          <year>2011</year>
<volume>36</volume>
<fpage>133</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2010.96</pub-id>
<pub-id pub-id-type="pmid">20631684</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Coulter</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>Cortical synaptic NMDA receptor deficits in alpha7 nicotinic acetylcholine receptor gene deletion models: implications for neuropsychiatric diseases</article-title>
<source/>Neurobiol Dis
          <year>2014</year>
<volume>63</volume>
<fpage>129</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2013.11.021</pub-id>
<pub-id pub-id-type="pmid">24326163</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nolt</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hruska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sheffler-Colins</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Kayser</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Passer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Zukin</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Dalva</surname>
<given-names>MB</given-names>
</name>
</person-group>
<article-title>EphB controls NMDA receptor function and synaptic targeting in a subunit-specific manner</article-title>
<source/>J Neurosci
          <year>2011</year>
<volume>31</volume>
<fpage>5353</fpage>
<lpage>5364</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0282-11.2011</pub-id>
<pub-id pub-id-type="pmid">21471370</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Frigge</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Masson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Besenbacher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sulem</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Magnusson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gudjonsson</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Sigurdsson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jonasdottir</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jonasdottir</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Sigurdsson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Helgason</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Thorleifsson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gudbjartsson</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Helgason</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Magnusson</surname>
<given-names>OT</given-names>
</name>
<name>
<surname>Thorsteinsdottir</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Stefansson</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Rate of de novo mutations and the importance of father’s age to disease risk</article-title>
<source/>Nature
          <year>2012</year>
<volume>488</volume>
<fpage>471</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="doi">10.1038/nature11396</pub-id>
<pub-id pub-id-type="pmid">22914163</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Pichon</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kibiryeva</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Graf</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Bittel</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Genome-wide gene expression in a patient with 15q13.3 homozygous microdeletion syndrome</article-title>
<source/>Eur J Hum Genet
          <year>2013</year>
<volume>21</volume>
<fpage>1093</fpage>
<lpage>1099</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2013.1</pub-id>
<pub-id pub-id-type="pmid">23361223</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghaleiha</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ghyasvand</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mohammadi</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Farokhnia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yadegari</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tabrizi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hajiaghaee</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yekehtaz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Akhondzadeh</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial</article-title>
<source/>J Psychopharmacol
          <year>2013</year>
<volume>28</volume>
<fpage>677</fpage>
<lpage>685</lpage>
<pub-id pub-id-type="doi">10.1177/0269881113508830</pub-id>
<pub-id pub-id-type="pmid">24132248</pub-id>
</element-citation>
</ref>
<ref id="CR191">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angelidou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alysandratos</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Asadi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Vasiadi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kalogeromitros</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Theoharides</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Brief report: “allergic symptoms” in children with autism spectrum disorders. More than meets the eye?</article-title>
<source/>J Autism Dev Disord
          <year>2011</year>
<volume>41</volume>
<fpage>1579</fpage>
<lpage>1585</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-010-1171-z</pub-id>
<pub-id pub-id-type="pmid">21210299</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Theoharides</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Angelidou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alysandratos</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Asadi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Toniato</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kalogeromitros</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Mast cell activation and autism</article-title>
<source/>Biochim Biophys Acta
          <year>2012</year>
<volume>1822</volume>
<fpage>34</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2010.12.017</pub-id>
<pub-id pub-id-type="pmid">21193035</pub-id>
</element-citation>
</ref>
<ref id="CR193">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romagnani</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Cytokines and chemoattractants in allergic inflammation</article-title>
<source/>Mol Immunol
          <year>2002</year>
<volume>38</volume>
<fpage>881</fpage>
<lpage>885</lpage>
<pub-id pub-id-type="doi">10.1016/S0161-5890(02)00013-5</pub-id>
<pub-id pub-id-type="pmid">12009564</pub-id>
</element-citation>
</ref>
<ref id="CR194">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Georas</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>De Fanis</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Casolaro</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>T-helper cell type-2 regulation in allergic disease</article-title>
<source/>Eur Respir J
          <year>2005</year>
<volume>26</volume>
<fpage>1119</fpage>
<lpage>1137</lpage>
<pub-id pub-id-type="doi">10.1183/09031936.05.00006005</pub-id>
<pub-id pub-id-type="pmid">16319345</pub-id>
</element-citation>
</ref>
<ref id="CR195">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sica</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mantovani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Macrophage plasticity and polarization: in vivo veritas</article-title>
<source/>J Clin Invest
          <year>2012</year>
<volume>122</volume>
<fpage>787</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="doi">10.1172/JCI59643</pub-id>
<pub-id pub-id-type="pmid">22378047</pub-id>
</element-citation>
</ref>
<ref id="CR196">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Leak</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Suenaga</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Microglial and macrophage polarization-new prospects for brain repair</article-title>
<source/>Nat Rev Neurol
          <year>2015</year>
<volume>11</volume>
<fpage>56</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1038/nrneurol.2014.207</pub-id>
<pub-id pub-id-type="pmid">25385337</pub-id>
</element-citation>
</ref>
<ref id="CR197">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Ashar</surname>
<given-names>FN</given-names>
</name>
<name>
<surname>Moes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bader</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>West</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Arking</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism</article-title>
<source/>Nat Commun
          <year>2014</year>
<volume>5</volume>
<fpage>5748</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms6748</pub-id>
<pub-id pub-id-type="pmid">25494366</pub-id>
</element-citation>
</ref>
<ref id="CR198">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegert</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Abernethy</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Depression in multiple sclerosis: a review</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2005</year>
<volume>76</volume>
<fpage>469</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.2004.054635</pub-id>
<pub-id pub-id-type="pmid">15774430</pub-id>
</element-citation>
</ref>
<ref id="CR199">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stys</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Zamponi</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>van Minnen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Geurts</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Will the real multiple sclerosis please stand up?</article-title>
<source/>Nat Rev Neurosci
          <year>2012</year>
<volume>13</volume>
<fpage>507</fpage>
<lpage>514</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3275</pub-id>
<pub-id pub-id-type="pmid">22714021</pub-id>
</element-citation>
</ref>
<ref id="CR200">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hemmer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nessler</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kieseier</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hartung</surname>
<given-names>HP</given-names>
</name>
</person-group>
<article-title>Immunopathogenesis and immunotherapy of multiple sclerosis</article-title>
<source/>Nat Clin Pract Neurol
          <year>2006</year>
<volume>2</volume>
<fpage>201</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1038/ncpneuro0154</pub-id>
<pub-id pub-id-type="pmid">16932551</pub-id>
</element-citation>
</ref>
<ref id="CR201">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nizri</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Irony-Tur-Sinai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lory</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Orr-Urtreger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lavi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brenner</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses</article-title>
<source/>J Immunol.
          <year>2009</year>
<volume>183</volume>
<fpage>6681</fpage>
<lpage>6688</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.0902212</pub-id>
<pub-id pub-id-type="pmid">19846875</pub-id>
</element-citation>
</ref>
<ref id="CR202">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hilker</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Weisenbach</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kalbe</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Burghaus</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Herholz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Heiss</surname>
<given-names>WD</given-names>
</name>
</person-group>
<article-title>Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways</article-title>
<source/>Neurology
          <year>2005</year>
<volume>65</volume>
<fpage>1716</fpage>
<lpage>1722</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000191154.78131.f6</pub-id>
<pub-id pub-id-type="pmid">16344512</pub-id>
</element-citation>
</ref>
<ref id="CR203">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimada</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hirano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shinotoh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Aotsuka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ota</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Asahina</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fukushi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kuwabara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suhara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Irie</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET</article-title>
<source/>Neurology
          <year>2009</year>
<volume>73</volume>
<fpage>273</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181ab2b58</pub-id>
<pub-id pub-id-type="pmid">19474411</pub-id>
</element-citation>
</ref>
<ref id="CR204">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bohnen</surname>
<given-names>NI</given-names>
</name>
<name>
<surname>Kaufer</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Ivanco</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Lopresti</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Koeppe</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Mathis</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>RY</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study</article-title>
<source/>Arch Neurol
          <year>2003</year>
<volume>60</volume>
<fpage>1745</fpage>
<lpage>1748</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.60.12.1745</pub-id>
<pub-id pub-id-type="pmid">14676050</pub-id>
</element-citation>
</ref>
<ref id="CR205">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emre</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aarsland</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Albanese</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Byrne</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Deuschl</surname>
<given-names>G</given-names>
</name>
<name>
<surname>De Deyn</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Durif</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kulisevsky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Laar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Poewe</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Robillard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rosa</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Wolters</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Quarg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tekin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Rivastigmine for dementia associated with Parkinson’s disease</article-title>
<source/>N Engl J Med
          <year>2004</year>
<volume>351</volume>
<fpage>2509</fpage>
<lpage>2518</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa041470</pub-id>
<pub-id pub-id-type="pmid">15590953</pub-id>
</element-citation>
</ref>
<ref id="CR206">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stuckenholz</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bacher</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Balzer-Geldsetzer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alvarez-Fischer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Oertel</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Dodel</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Noelker</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The alpha7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice</article-title>
<source/>J Parkinsons Dis
          <year>2013</year>
<volume>3</volume>
<fpage>161</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="pmid">23938346</pub-id>
</element-citation>
</ref>
<ref id="CR207">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kawamata</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Matsushita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsumura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hisahara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kitamura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kem</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Shimohama</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through alpha7 nicotinic acetylcholine receptor stimulation in rats</article-title>
<source/>J Neurosci Res
          <year>2013</year>
<volume>91</volume>
<fpage>462</fpage>
<lpage>471</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.23160</pub-id>
<pub-id pub-id-type="pmid">23239187</pub-id>
</element-citation>
</ref>
<ref id="CR208">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Activation of alpha7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson’s disease</article-title>
<source/>Neuropharmacology
          <year>2015</year>
<volume>91</volume>
<fpage>87</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.11.028</pub-id>
<pub-id pub-id-type="pmid">25486621</pub-id>
</element-citation>
</ref>
<ref id="CR209">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bordia</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Grady</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>McIntosh</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Quik</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson’s disease striatum</article-title>
<source/>Mol Pharmacol
          <year>2007</year>
<volume>72</volume>
<fpage>52</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1124/mol.107.035998</pub-id>
<pub-id pub-id-type="pmid">17409284</pub-id>
</element-citation>
</ref>
<ref id="CR210">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsch</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Hunot</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Neuroinflammation in Parkinson’s disease: a target for neuroprotection?</article-title>
<source/>Lancet Neurol
          <year>2009</year>
<volume>8</volume>
<fpage>382</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(09)70062-6</pub-id>
<pub-id pub-id-type="pmid">19296921</pub-id>
</element-citation>
</ref>
<ref id="CR211">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aarsland</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pahlhagen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Ehrt</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Svenningsson</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Depression in Parkinson disease—epidemiology, mechanisms and management</article-title>
<source/>Nat Rev Neurol
          <year>2012</year>
<volume>8</volume>
<fpage>35</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1038/nrneurol.2011.189</pub-id>
<pub-id pub-id-type="pmid">22198405</pub-id>
</element-citation>
</ref>
<ref id="CR212">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacob</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Gatto</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bordelon</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ritz</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Occurrence of depression and anxiety prior to Parkinson’s disease</article-title>
<source/>Parkinsonism Relat Disord
          <year>2010</year>
<volume>16</volume>
<fpage>576</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2010.06.014</pub-id>
<pub-id pub-id-type="pmid">20674460</pub-id>
</element-citation>
</ref>
<ref id="CR213">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindqvist</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kaufman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brundin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Surova</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hansson</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Non-motor symptoms in patients with Parkinson’s disease—correlations with inflammatory cytokines in serum</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e47387</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0047387</pub-id>
<pub-id pub-id-type="pmid">23082161</pub-id>
</element-citation>
</ref>
<ref id="CR214">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beumer</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gibney</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Drexhage</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Pont-Lezica</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Doorduin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Connor</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Harkin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Versnel</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Drexhage</surname>
<given-names>HA</given-names>
</name>
</person-group>
<article-title>The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes</article-title>
<source/>J Leukoc Biol
          <year>2012</year>
<volume>92</volume>
<fpage>959</fpage>
<lpage>975</lpage>
<pub-id pub-id-type="doi">10.1189/jlb.0212100</pub-id>
<pub-id pub-id-type="pmid">22875882</pub-id>
</element-citation>
</ref>
<ref id="CR215">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulak</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys</article-title>
<source/>Brain Res
          <year>2004</year>
<volume>999</volume>
<fpage>193</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2003.10.062</pub-id>
<pub-id pub-id-type="pmid">14759498</pub-id>
</element-citation>
</ref>
<ref id="CR216">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feuerbach</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pezous</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shakeri-Nejad</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lingenhoehl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hoyer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hurth</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bilbe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pryce</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>McAllister</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chaperon</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kucher</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Johns</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Blaettler</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lopez Lopez</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>AQW051, a novel, potent and selective alpha7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation</article-title>
<source/>Br J Pharmacol
          <year>2015</year>
<volume>172</volume>
<fpage>1292</fpage>
<lpage>1304</lpage>
<pub-id pub-id-type="doi">10.1111/bph.13001</pub-id>
<pub-id pub-id-type="pmid">25363835</pub-id>
</element-citation>
</ref>
<ref id="CR217">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perry</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Teeling</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration</article-title>
<source/>Semin Immunopathol
          <year>2013</year>
<volume>35</volume>
<fpage>601</fpage>
<lpage>612</lpage>
<pub-id pub-id-type="doi">10.1007/s00281-013-0382-8</pub-id>
<pub-id pub-id-type="pmid">23732506</pub-id>
</element-citation>
</ref>
<ref id="CR218">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimizu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kajizono</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1–42) by rat primary type 2 microglia</article-title>
<source/>J Immunol
          <year>2008</year>
<volume>181</volume>
<fpage>6503</fpage>
<lpage>6513</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.181.9.6503</pub-id>
<pub-id pub-id-type="pmid">18941241</pub-id>
</element-citation>
</ref>
<ref id="CR219">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harry</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Microglia during development and aging</article-title>
<source/>Pharmacol Ther
          <year>2013</year>
<volume>139</volume>
<fpage>313</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.04.013</pub-id>
<pub-id pub-id-type="pmid">23644076</pub-id>
</element-citation>
</ref>
<ref id="CR220">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernandez</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Kayed</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sweatt</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Dineley</surname>
<given-names>KT</given-names>
</name>
</person-group>
<article-title>Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer’s disease</article-title>
<source/>J Neurosci
          <year>2010</year>
<volume>30</volume>
<fpage>2442</fpage>
<lpage>2453</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5038-09.2010</pub-id>
<pub-id pub-id-type="pmid">20164328</pub-id>
</element-citation>
</ref>
<ref id="CR221">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0118333</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0118333</pub-id>
<pub-id pub-id-type="pmid">25763939</pub-id>
</element-citation>
</ref>
<ref id="CR222">
<label>222.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fratiglioni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>HX</given-names>
</name>
</person-group>
<article-title>Smoking and Parkinson’s and Alzheimer’s disease: review of the epidemiological studies</article-title>
<source/>Behav Brain Res
          <year>2000</year>
<volume>113</volume>
<fpage>117</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="doi">10.1016/S0166-4328(00)00206-0</pub-id>
<pub-id pub-id-type="pmid">10942038</pub-id>
</element-citation>
</ref>
<ref id="CR223">
<label>223.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parri</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Dineley</surname>
<given-names>KT</given-names>
</name>
</person-group>
<article-title>Research update: alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer’s disease</article-title>
<source/>Biochem Pharmacol
          <year>2011</year>
<volume>82</volume>
<fpage>931</fpage>
<lpage>942</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2011.06.039</pub-id>
<pub-id pub-id-type="pmid">21763291</pub-id>
</element-citation>
</ref>
<ref id="CR224">
<label>224.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Simard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>DeChon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lucero</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sierks</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lukas</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides</article-title>
<source/>J Neurosci
          <year>2009</year>
<volume>29</volume>
<fpage>918</fpage>
<lpage>929</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3952-08.2009</pub-id>
<pub-id pub-id-type="pmid">19176801</pub-id>
</element-citation>
</ref>
<ref id="CR225">
<label>225.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomsen</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Zwart</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ursu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Pinborg</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Gilmour</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sher</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mikkelsen</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>alpha7 and beta2 nicotinic acetylcholine receptor subunits form heteromeric receptor complexes that are expressed in the human cortex and display distinct pharmacological properties</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0130572</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0130572</pub-id>
<pub-id pub-id-type="pmid">26086615</pub-id>
</element-citation>
</ref>
<ref id="CR226">
<label>226.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foster</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Conn</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling</article-title>
<source/>Discov Med
          <year>2012</year>
<volume>14</volume>
<fpage>413</fpage>
<lpage>420</lpage>
<pub-id pub-id-type="pmid">23272693</pub-id>
</element-citation>
</ref>
<ref id="CR227">
<label>227.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geerts</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>alpha7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer’s disease</article-title>
<source/>Expert Opin Investig Drugs
          <year>2012</year>
<volume>21</volume>
<fpage>59</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1517/13543784.2012.633510</pub-id>
<pub-id pub-id-type="pmid">22047592</pub-id>
</element-citation>
</ref>
<ref id="CR228">
<label>228.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valles</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Barrantes</surname>
<given-names>FJ</given-names>
</name>
</person-group>
<article-title>Targeting brain alpha7 nicotinic acetylcholine receptors in Alzheimer’s disease: rationale and current status</article-title>
<source/>CNS Drugs
          <year>2014</year>
<volume>28</volume>
<fpage>975</fpage>
<lpage>987</lpage>
<pub-id pub-id-type="doi">10.1007/s40263-014-0201-3</pub-id>
<pub-id pub-id-type="pmid">25248971</pub-id>
</element-citation>
</ref>
<ref id="CR229">
<label>229.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olincy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Pender</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kongs</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Allensworth</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zerbe</surname>
<given-names>GO</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Soti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kem</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia</article-title>
<source/>Arch Gen Psychiatry
          <year>2006</year>
<volume>63</volume>
<fpage>630</fpage>
<lpage>638</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.63.6.630</pub-id>
<pub-id pub-id-type="pmid">16754836</pub-id>
</element-citation>
</ref>
<ref id="CR230">
<label>230.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feuerbach</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lingenhoehl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Olpe</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Vassout</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gentsch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chaperon</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nozulak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Enz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bilbe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>McAllister</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hoyer</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain</article-title>
<source/>Neuropharmacology
          <year>2009</year>
<volume>56</volume>
<fpage>254</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.08.025</pub-id>
<pub-id pub-id-type="pmid">18793655</pub-id>
</element-citation>
</ref>
<ref id="CR231">
<label>231.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevens</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Cornejo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yonchek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Christians</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Kem</surname>
<given-names>WR</given-names>
</name>
</person-group>
<article-title>Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice</article-title>
<source/>Brain Res
          <year>2010</year>
<volume>1352</volume>
<fpage>140</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2010.06.063</pub-id>
<pub-id pub-id-type="pmid">20599427</pub-id>
</element-citation>
</ref>
<ref id="CR232">
<label>232.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tregellas</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Olincy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shatti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Singel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>YP</given-names>
</name>
<name>
<surname>Soti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kem</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia</article-title>
<source/>Neuropsychopharmacology
          <year>2010</year>
<volume>35</volume>
<fpage>938</fpage>
<lpage>942</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2009.196</pub-id>
<pub-id pub-id-type="pmid">19956085</pub-id>
</element-citation>
</ref>
<ref id="CR233">
<label>233.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papke</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nutter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Uteshev</surname>
<given-names>VV</given-names>
</name>
</person-group>
<article-title>alpha7 receptor-selective agonists and modes of alpha7 receptor activation</article-title>
<source/>Eur J Pharmacol
          <year>2000</year>
<volume>393</volume>
<fpage>179</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-2999(00)00009-1</pub-id>
<pub-id pub-id-type="pmid">10771012</pub-id>
</element-citation>
</ref>
<ref id="CR234">
<label>234.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tietje</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Bitner</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Blomme</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Brackemeyer</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Briggs</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Browman</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Bury</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Curzon</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Drescher</surname>
<given-names>KU</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Gronlien</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Hakerud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gubbins</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Halm</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Helfrich</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Kohlhaas</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Malysz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Molesky</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Nikkel</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Otte</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Puttfarcken</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Radek</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Robb</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Spies</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Thorin-Hagene</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Waring</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Ween</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gopalakrishnan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bunnelle</surname>
<given-names>WH</given-names>
</name>
</person-group>
<article-title>Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties</article-title>
<source/>CNS Neurosci Ther
          <year>2008</year>
<volume>14</volume>
<fpage>65</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1111/j.1755-5949.2008.00037.x</pub-id>
<pub-id pub-id-type="pmid">18482100</pub-id>
</element-citation>
</ref>
<ref id="CR235">
<label>235.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arias</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>RX</given-names>
</name>
<name>
<surname>Feuerbach</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>DQ</given-names>
</name>
</person-group>
<article-title>Different interaction between the agonist JN403 and the competitive antagonist methyllycaconitine with the human alpha7 nicotinic acetylcholine receptor</article-title>
<source/>Biochemistry
          <year>2010</year>
<volume>49</volume>
<fpage>4169</fpage>
<lpage>4180</lpage>
<pub-id pub-id-type="doi">10.1021/bi901999v</pub-id>
<pub-id pub-id-type="pmid">20377277</pub-id>
</element-citation>
</ref>
<ref id="CR236">
<label>236.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prickaerts</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Goethem</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Chesworth</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Boess</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Methfessel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reneerkens</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Flood</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Hilt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gawryl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Konig</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors</article-title>
<source/>Neuropharmacology
          <year>2012</year>
<volume>62</volume>
<fpage>1099</fpage>
<lpage>1110</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.10.024</pub-id>
<pub-id pub-id-type="pmid">22085888</pub-id>
</element-citation>
</ref>
<ref id="CR237">
<label>237.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cachelin</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Rust</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Unusual pharmacology of (+)-tubocurarine with rat neuronal nicotinic acetylcholine receptors containing beta 4 subunits</article-title>
<source/>Mol Pharmacol
          <year>1994</year>
<volume>46</volume>
<fpage>1168</fpage>
<lpage>1174</lpage>
<pub-id pub-id-type="pmid">7808438</pub-id>
</element-citation>
</ref>
<ref id="CR238">
<label>238.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smyth</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Lawrie</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>The neuroimmunology of schizophrenia</article-title>
<source/>Clin Psychopharmacol Neurosci
          <year>2013</year>
<volume>11</volume>
<fpage>107</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.9758/cpn.2013.11.3.107</pub-id>
<pub-id pub-id-type="pmid">24465246</pub-id>
</element-citation>
</ref>
<ref id="CR239">
<label>239.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steiner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bielau</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Brisch</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Danos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ullrich</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Mawrin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Bogerts</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide</article-title>
<source/>J Psychiatr Res
          <year>2008</year>
<volume>42</volume>
<fpage>151</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2006.10.013</pub-id>
<pub-id pub-id-type="pmid">17174336</pub-id>
</element-citation>
</ref>
<ref id="CR240">
<label>240.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janelidze</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mattei</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Westrin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Traskman-Bendz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brundin</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Cytokine levels in the blood may distinguish suicide attempters from depressed patients</article-title>
<source/>Brain Behav Immun
          <year>2011</year>
<volume>25</volume>
<fpage>335</fpage>
<lpage>339</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2010.10.010</pub-id>
<pub-id pub-id-type="pmid">20951793</pub-id>
</element-citation>
</ref>
<ref id="CR241">
<label>241.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erhardt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Linderholm</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Janelidze</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lindqvist</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Samuelsson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lundberg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Postolache</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Traskman-Bendz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Brundin</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Connecting inflammation with glutamate agonism in suicidality</article-title>
<source/>Neuropsychopharmacology
          <year>2013</year>
<volume>38</volume>
<fpage>743</fpage>
<lpage>752</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2012.248</pub-id>
<pub-id pub-id-type="pmid">23299933</pub-id>
</element-citation>
</ref>
<ref id="CR242">
<label>242.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schnieder</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Trencevska</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rosoklija</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Stankov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Smiley</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dwork</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Microglia of prefrontal white matter in suicide</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2014</year>
<volume>73</volume>
<fpage>880</fpage>
<lpage>890</lpage>
<pub-id pub-id-type="doi">10.1097/NEN.0000000000000107</pub-id>
<pub-id pub-id-type="pmid">25101704</pub-id>
</element-citation>
</ref>
<ref id="CR243">
<label>243.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brundin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Erhardt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bryleva</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>Achtyes</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Postolache</surname>
<given-names>TT</given-names>
</name>
</person-group>
<article-title>The role of inflammation in suicidal behaviour</article-title>
<source/>Acta Psychiatr Scand
          <year>2015</year>
<volume>132</volume>
<fpage>192</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1111/acps.12458</pub-id>
<pub-id pub-id-type="pmid">26256862</pub-id>
</element-citation>
</ref>
<ref id="CR244">
<label>244.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freland</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Beaulieu</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Inhibition of GSK3 by lithium, from single molecules to signaling networks</article-title>
<source/>Front Mol Neurosci
          <year>2012</year>
<volume>5</volume>
<fpage>14</fpage>
<pub-id pub-id-type="doi">10.3389/fnmol.2012.00014</pub-id>
<pub-id pub-id-type="pmid">22363263</pub-id>
</element-citation>
</ref>
<ref id="CR245">
<label>245.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beurel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Michalek</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Jope</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3)</article-title>
<source/>Trends Immunol
          <year>2010</year>
<volume>31</volume>
<fpage>24</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/j.it.2009.09.007</pub-id>
<pub-id pub-id-type="pmid">19836308</pub-id>
</element-citation>
</ref>
<ref id="CR246">
<label>246.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Tondo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hennen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Lithium treatment and suicide risk in major affective disorders: update and new findings</article-title>
<source/>J Clin Psychiatry
          <year>2003</year>
<volume>64</volume>
<issue>Suppl 5</issue>
<fpage>44</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">12720484</pub-id>
</element-citation>
</ref>
<ref id="CR247">
<label>247.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beurel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jope</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits</article-title>
<source/>Transl Psychiatry
          <year>2014</year>
<volume>4</volume>
<fpage>e488</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2014.129</pub-id>
<pub-id pub-id-type="pmid">25514751</pub-id>
</element-citation>
</ref>
<ref id="CR248">
<label>248.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Sarno</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Axtell</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Raman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Alessi</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Jope</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Lithium prevents and ameliorates experimental autoimmune encephalomyelitis</article-title>
<source/>J Immunol
          <year>2008</year>
<volume>181</volume>
<fpage>338</fpage>
<lpage>345</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.181.1.338</pub-id>
<pub-id pub-id-type="pmid">18566399</pub-id>
</element-citation>
</ref>
<ref id="CR249">
<label>249.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Avila</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Full reversal of Alzheimer’s disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3</article-title>
<source/>J Neurosci
          <year>2006</year>
<volume>26</volume>
<fpage>5083</fpage>
<lpage>5090</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0604-06.2006</pub-id>
<pub-id pub-id-type="pmid">16687499</pub-id>
</element-citation>
</ref>
<ref id="CR250">
<label>250.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiorentini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rosi</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Grossi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Luccarini</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Casamenti</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice</article-title>
<source/>PLoS One
          <year>2010</year>
<volume>5</volume>
<fpage>e14382</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0014382</pub-id>
<pub-id pub-id-type="pmid">21187954</pub-id>
</element-citation>
</ref>
<ref id="CR251">
<label>251.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Heng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Doody</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer’s disease transgenic mouse model</article-title>
<source/>J Alzheimers Dis
          <year>2011</year>
<volume>24</volume>
<fpage>739</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="pmid">21321394</pub-id>
</element-citation>
</ref>
<ref id="CR252">
<label>252.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youdim</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Arraf</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Prevention of MPTP (<italic>N</italic>-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax</article-title>
<source/>Neuropharmacology
          <year>2004</year>
<volume>46</volume>
<fpage>1130</fpage>
<lpage>1140</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.02.005</pub-id>
<pub-id pub-id-type="pmid">15111020</pub-id>
</element-citation>
</ref>
<ref id="CR253">
<label>253.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lieu</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Dewey</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Chinta</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Rane</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rajagopalan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Batir</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model</article-title>
<source/>Brain Res
          <year>2014</year>
<volume>1591</volume>
<fpage>111</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2014.10.032</pub-id>
<pub-id pub-id-type="pmid">25452026</pub-id>
</element-citation>
</ref>
<ref id="CR254">
<label>254.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lazzara</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Riley</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Rane</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YH</given-names>
</name>
</person-group>
<article-title>The combination of lithium and <sc>l</sc>-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: relevance for Parkinsons disease therapy</article-title>
<source/>Brain Res
          <year>2015</year>
<volume>1622</volume>
<fpage>127</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2015.06.018</pub-id>
<pub-id pub-id-type="pmid">26119916</pub-id>
</element-citation>
</ref>
<ref id="CR255">
<label>255.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Paolo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gregoire</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Feuerbach</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Elbast</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gomez-Mancilla</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces <sc>l</sc>-Dopa-induced dyskinesias and extends the duration of <sc>l</sc>-Dopa effects in parkinsonian monkeys</article-title>
<source/>Parkinsonism Relat Disord
          <year>2014</year>
<volume>20</volume>
<fpage>1119</fpage>
<lpage>1123</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.05.007</pub-id>
<pub-id pub-id-type="pmid">25172125</pub-id>
</element-citation>
</ref>
<ref id="CR256">
<label>256.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>McGregor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Decker</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Quik</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The alpha7 nicotinic receptor agonist ABT-107 decreases <sc>l</sc>-Dopa-induced dyskinesias in parkinsonian monkeys</article-title>
<source/>J Pharmacol Exp Ther
          <year>2014</year>
<volume>351</volume>
<fpage>25</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.114.216283</pub-id>
<pub-id pub-id-type="pmid">25034405</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>